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Abstract
The purpose of this research is to inspect the statistical power of studies that investigate
the effects of low dose ionizing radiation on the incidence of/mortality from cancer. I use
a procedure proposed in a similar study to handle a problem regarding the incidence of
childhood leukemia from background ionizing radiation. I study this procedure critically
and make some adjustments to make its performance better. I also propose some substitute
methods to the methods proposed in the aforementioned reference in order to calculate
the power. In addition, I propose other methods not used in the study mentioned above.
I evaluate the efficiency of my proposed approaches using simulated data. The improved
method can be applied to the National Dose Registry of Canada (NDR) to produce the
power curves. The outcomes then can be used to propose the most suitable study design.
Some of the previous epidemiological studies based on NDR can also be evaluated in terms
of power.
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Chapter 1
Preliminaries
In this chapter first, I explain the motivations for carrying out this research. Then, I
present the concept of statistical power (henceforth I will refer to it simply as power), and
its calculation based on closed-form formulas and simulations. I also discuss factors that can
potentially impact the power of study design. Since my study mainly deals with cohort and
case-control studies, I then define these two study designs in a general context.
1.1 Motivations for the study
As described in Gordis (2014; page 7): “Epidemiologic reasoning is whether an association
exists between exposure to a factor”. Depending on the study design the association is
evaluated based on some measures of association such as the risk ratio (RR) in cohort
studies and the odds ratio (OR) in case-control studies (Ahrens and Pigeot. 2015; Chapters
I.5 and I.6). If RR/OR falls between 0 and 1, the association is interpreted as being inverse
or negative, i.e., an increase in the exposure is associated with a decrease in the outcome
variable. On the other hand, a value of RR/OR greater than 1 indicates a positive/direct
association between the exposure and the outcome variable. Note that 1 is the null value
for RR/OR, implying that there is no association between the exposure and the outcome
variable. In practice, the RR/OR is an unknown quantity and is estimated from a sample.
Then we rely on statistical methods to test whether or not it is significantly different from the
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null value 1. An insignificant result leads to the conclusion that there is not enough evidence
to support the association between the exposure and the outcome. In general, significance is
determined through a hypothesis test. It should be noted that an insignificant result might
stem from several factors, including:
1. no true association between the exposure and the outcome,
2. selection and/or information bias (Gordis 2014; Chapter 15),
3. low power to detect an association (Ellis 2010; Chapter 1).
Therefore, knowledge about power is importnat. The reason is that if the epidemiologists
already control the bias and are informed that the power of their study is high enough, then
a non-significant result can be considered as a strong evidence of no association between the
exposure and the outcome. Otherwise, if the power is low, the non-significant result should
not be interpreted as the lack of association. In general, the power of a statistical test is
defined as the probability of rejecting the null hypothesis when it is true (i.e., the probability
of making a correct decision). In this regard, a low power indicates higher uncertainty as to
whether a statistically insignificant result is due to an actual lack of difference or simply due
to the sample size that is insufficient to detect the effects of the exposure.
Knowledge regarding the power of a study is crucially important: if the researcher is aware
that the study is powerful enough, then an insignificant result could be strong evidence that
there is truly no association (provided that other issues such as bias are also under control).
By contrast, if he/she knows that the study has low power, then the insignificant association
should not be interpreted as a lack of association.
In this research, the exposure and outcome of interest are exposed to low dose levels of
ionizing radiation and all health outcomes of cancer (incidence or mortality), respectively.
In the next section, I will briefly present different types of studies that try to detect an
association between the aforementioned exposure and outcome. One type of such study
2
is occupational studies that aim to establish the association by studying occupations that
are exposed to low dose levels of ionizing radiation, yet higher than that of the general
public (Beebe et al. 1998, Richardson and Wing 1999, Sun et al. 2016). Examples of such
occupations are nuclear plant workers and health workers such as dentists, nurses, etc. The
National Dose Registry (NDR) of Canada (NDR website 2020) is a database which has been
recording the information of such workers since 1951. Epidemiological researches in the area
of ionizing radiation and cancer have been carried out based on this database. A couple
of such studies are Ashmore et al. (1998), Gribbin et al. (1993). Each of these studies has
covered different periods and consequently, they have different sample sizes. As a result (as
will be explained in the coming sections) they have different powers to detect the association.
my purpose is to determine the power of NDR-based studies for different periods of
follow-up. In this way, I will be able to relax the epidemiologist’s concern regarding the
power as explained above. In particular, I will answer the following questions:
1. What is the best study design in terms of power? cohort or case-control? Also, what
is the optimum number of controls per case for the case-control study?
2. Have the previous studies been powerful enough to detect an effect?
1.2 About the cohort and case-control studies
Cohort and case-control studies are two very common study designs in epidemiology.
Most ionizing radiation-cancer studies are of these two types. The main difference between
the two designs is that the cohort study starts with individuals whose exposure status is
known. They are followed up for some time to determine the status of the outcome. In
comparison, the case-control studies first determine the status of the outcome and then try
to find the history of exposure. More precisely the two study designs are defined in Gordis
(2014) as follows:
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• Cohort study. “In a cohort study, the investigator selects a group of exposed individuals
and a group of non-exposed individuals and follows up both groups to compare the
incidence of disease (or rate of death from disease) in the two groups. The design may
include more than two groups, although only two groups are shown for diagrammatic
purposes.” (Gordis 2014; Chapter 9)
• Case-control study. “We begin by selecting cases (with the disease) and controls
(without the disease), and then measure past exposure by interview and by review of
medical or employee records or of results of chemical or biologic assays of blood, urine,
or tissues.” (Gordis 2014; Chapter 10)
The most commonly used measure of association in cohort studies is the Risk Ratio (RR).
If both exposure and outcome are binary (i.e. two possible outcomes), then RR is defined as
RR =
Probability of being a case in exposed group
Probability of being a case in non-exposed group
=
a/(a + b)
c/(c + d)
, (1.1)
where a and b are, respectively, the number of cases and non-cases in the exposed group
, and c and d are those in the non-exposed group (See Table 1.1). Risk ratio can also be
written as RR = 1 + ERR where ERR is defined as the Excess Relative Risk.
The odds ratio is the most commonly used measure of association for case-control studies,
defined as
OR =
Odds of being exposed as a case
Odds of being exposed as a control
=
a/c
b/d
(1.2)
where a and c are numbers of exposed and non-exposed cases, respectively. b and d are
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number of exposed and non-exposed controls, respectively (See Table 1.1). The odds ratio
can be written as OR = 1 + EOR where EOR is the Excess Odds Ratio.
Table 1.1: Contingency table for cohort and case-control studies
Remark 1.1. It is proven in Greenland and Thomas (1982) that when the outcome of interest
is rare, the odds ratio and risk ratio are almost equal.
1.3 Power
Assume that we are testing H0 : θ ∈ Θ0 versus H1 : θ ∈ Θc0. This test can make two types
of errors (Casella and Berger 1990; Section 8.3):
1. type I error: if the true parameter belongs to Θ0 but the test rejects it in favor of
θ ∈ Θc0, then a type I error has occurred.
2. type II error: if the true parameter belongs to Θc0 but the test decides not to reject
the null in favor of θ ∈ Θc0, then a type II error has occurred.
The probability of the complement of type II error is called the power of the test. Therefore,
the power of a test is the probability to truly reject the null in favor of the alternative. In
epidemiological terms, the power is usually interpreted as the ability to detect an effect when
it truly exists. In every hypothesis test we have two competing factors that we would like to
optimize: On one hand, we want to keep the probability of the type I error to a minimum.
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On the other hand, we try to maximize the power of the test. As will be explained in the
next section, optimizing any of these factors hurts the optimality of the other one.
In many cases, the null hypothesis has a simple form H0 : θ = θ0 for some θ0. In such a
case, the alternative is usually H1 : θ , θ0. Calculating the power then requires finding the
distribution of the test statistic under the single value of θ0. However, when it comes to the
alternative, in practice, not all the parameters θ , θ0 are considered. Rather, usually a single
value θ1 , θ0 is picked. Then, to calculate the power, one way is to find the distribution of
the test statistic at the null under the alternative. This means that the formula of the test
statistic is calculated at θ = θ0 but the distribution of interest is the one with samples from
θ = θ1. Another way is to take samples from alternative and check whether the test statistic
under the null rejects it or not. The proportion of the rejections is then reported as power.
The value θ1 as defined above is usually the parameter which is believed to be the true
parameter or at least closer to θ0 than the true parameter. The latter means we need to find
the power for an effect size smaller than the true effect. In such a case we need a higher
power to detect θ1 and we can rest assured that with such a power we will be able to detect
the true parameter too.
1.3.1 Factors that impact the power of a test
There are mainly 4 factors that can impact the power of a test (Norton and Strube 2001).
Note that the first three factors as described below can directly change the power. Therefore,
the designer can change any of them to reach a higher power. The fourth factor, as described
below, is a kind of inherent and seems to be not adjustable. This is why most references do
not refer to this factor. However, we will give an example to show that in some cases one
can design the experiment in a way to obtain higher power even in case all the other three
factors are fixed.
Below, I explain the impact of each factor using a plot. For simplicity, I assume that
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the test statistic under both null and alternative is known and is normally distributed. The
dashed area in each figure represents the power of the test.
1. The significance level. The probability of the type I error is referred to as the sig-
nificance level (also, the size of the test (See Casella and Berger (1990; Section 8.3)).
There is a trade-off between the significance level and power. This means increasing
any of them causes the other one to increase as well. One simple explanation is that a
higher significance level means that we have to reject more often (we are conservative),
as a result, the chance of a correct rejection increases too, which means using threshold
we get higher power.
Figure 1.1: Two tests with α = 0.03 (left) and α = 0.05 (right), adjusted for the other
factors.
Figure 1.1 represents this fact (dashed area represents the power of the test). While
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the shape and position of the test statistic under both null and alternative remains the
same (as a result of keeping the sample size and the effect size fixed), increasing the
significance level shifts the dashed area to the left and causes the power to go up.
2. The effect size. As defined in Ellis (2010; Chapter 1): “An effect size refers to the
magnitude of the result as it occurs, or would be found, in the population”. It was
mentioned above that to calculate the power we usually fix one parameter in the
alternative space such as θ = θ1. The closer θ1 to θ0, the more mixed the distribution
under the null and alternative. As a result, the test statistic under the null is more
likely not to reject in favor of the alternative.
Figure 1.2: Two tests with θ0 = 0, θ1 = 1 (left) and θ1 = 3 (right), adjusted for the
other factors.
Figure 1.2 shows the impact of effect size on the power. Notice that the shapes of the
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test statistic and the start point of the dashed area remain the same (as a result of
keeping the sample size and the significance level fixed). However, shifting the test
statistic under alternative to the right in the right frame causes the power to increase.
3. The sample size. Larger sample size results in a higher power. A simple explanation
is that there is a reverse relationship between the sample size and the variance of the
test statistic under both null and alternative. For example, recall that the variance of
X¯ (the sample mean) which is the test statistic for the population mean is given by
σ√
n where σ is the variance of X and n is the sample size. This shows that a small
sample size causes the variance of the test statistic to increase. This makes the test
statistics under both null and alternative flatter and causes them to be more mixed
which results in lower power. This fact has been represented in Figure 1.3. While the
significance level and the effect size are the same in both tests, smaller sample size
results in a flatter shape on the left.
The effect of sample size on the power can also be justified using another argument.
By definition
power = P(Re ject|S hould be truly re jected).
In this definition, the condition part, i.e.“Should be truly rejected” refers to the real
population while the event, i.e.“Reject” refers to the sample. As a result, the larger the
sample size, the better the true state of the population reflects on the sample. This
results in more true rejections which imply higher power.
4. Variability in the data. The larger the variance of the sample, the larger the variance of
the test statistic. As explained for the impact of the sample size, the large variance of
the test statistic results in lower power. Again, a good example is X¯ where its variance
( σ√n) directly depends on the variance of the sample. The impact of the sample’s
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Figure 1.3: Two tests with different sizes: small (left) and large (right), adjusted for
the other factors.
variance can be similarly represented using Figure 1.3.
It should be pointed out that this factor is less studied as compared to the other three
factors. One main reason is that it seems to be inherent to the data and not fairly
adjustable. So, it can not be deployed to improve the power of the test. However, an
example is provided in Friedman et al. (2010; Chapter 8) to show that with a better
study design one can improve the power while keeping the sample size, the significance
level, and the effect size fixed. The example is regarding a clinical trial where the
impact of a new drug on the cholesterol level is of interest. The sample is divided
into the intervention and the control group. The impact of the drug can be measured
by comparing the mean value of the cholesterol level in two groups. There are two
possible designs. One can only measure the cholesterol level at the end of the trial and
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just compare the mean values in the two groups. Another possibility is to measure it
both at the beginning and the end of the trial, then calculate the differences for each
individual and finally make an inference by comparing the mean of the differences. It
is proven in Friedman et al. (2010; Chapter 8) that the latter trial results in lower
variance and consequently higher power.
1.3.2 Why Monte-Carlo simulation to find the power?
Calculation of power using the analytical method, i.e. based on a closed-form formula,
requires the distribution of the test statistic under both null and alternative to be known
(Landau and Sathi 2012). In many cases, there are some tools (particularly, asymptotic
tools) to deal with the distribution of the test statistic under the null. However, distribution
under the alternative is usually more awkward. If any of the two distributions can not
be determined analytically one needs to use sampling (Monte-Carlo simulation) to find the
power (Landau and Sathi 2012). Notice that even this latter approach requires information
about the distribution of samples when the true parameter is the alternative.
Apart from the case above, there are also some special complex cases which can be
handled better using Mont-Carlo simulation. Two of such cases are as follows (Monte-Carlo
for power 2019):
1. multiple tests: We would like to implement different tests at the same time. Such a
test is of the form
(H0i : θ ∈ Θ0i vs H1i : θ ∈ Θ1i )ni=1 .
2. multiple alternatives: We require at least one of the multiple alternative to be true.
This test is of the form
H0 : θ ∈ Θ0 vs H1 : (θ ∈ Θ1 or θ ∈ Θ2 · · · or θ ∈ Θn).
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1.3.3 Score test statistic
The test statistic that I use for my research is the score test statistic derived from some
specific likelihoods as described in Chapter 3 and 4.
Assume that we have a vector of parameters θ with the corresponding likelihood function
L. Then the score function is defined with
U(θ) = ∇(logL(θ)) = (∂logL(θ)
∂θi
)ni=1.
The fisher information is defined with
I(θ) = −E[∇2log(L(θ))|θ].
The score test statistic is then defined with
S (θ) = U(θ)T I(θ)−1U(θ).
Assume that θ is a vector of length p and assume that we want to test for H0 : θ = θ0. The
score test statistic for this hypothesis test is then S (θ0). In 1948, Rao proved that the score
test statistic under the null has asymptotic χ2p distribution (Rao 1948). In particular if θ is
a single parameter then S (θ) = U(θ)2var(U(θ)) has asymptotic χ21 distribution. Equivalently U(θ))√var(U(θ))
is asymptotically normally distributed.
Remark 1.2. At this point, we would like to highlight a point regarding terms such as “test
statistic under null” and “test statistic under the alternative”. Assume that we test H0 : θ = θ0
and we are interested in detecting effect θ = θ1. It should be carried in mind that the
test statistic under the alternative might be not necessarily the test statistic when we test
H0 : θ = θ1. In some simple cases, it turns out to be correct. For instance, in case of testing
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for the mean value of a normal population, the test statistic under the alternative is the
same as the test statistic under null when the null is H0 : θ = θ1. However, in general, this
might be not true. It seems that simple cases such as this, in addition to the vague nature
of the aforementioned terms, sometimes lead to confusion. Notice that when we use a term
such as“test statistic under the alternative” we are referring to the distribution of the test
statistic for the null when samples come from alternative! For example, if we use the score
test statistic, then by the distribution of the score test under the alternative we don’t mean
the distribution of S (θ1) but we mean the distribution of S (θ0) when samples come from θ1.
1.4 Organization of the thesis
I proceed in Chapter 2 by presenting a literature review on both ionizing radiation-
cancer studies and power studies of case-control and cohort designs. In Chapters 3 and 4 I
will discuss the power model for cohort and case-control studies, respectively. The models
have already been developed in Little et al. (2010). I will spot some problems regarding
the model and propose solutions. I also provide the algorithms required to implement the
model. In Chapter 4, I provide some additional results which can be used to improve the
performance of the model. I will address some points in Little et al. (2010) which seem to
require revision and propose substitute methods. Some other approaches to calculate power
are also presented. Based on a literature review, I provide required information such as the
break-down of the dose parameter and estimates for the ERR parameter. In Appendix A, I
use some simulated data to illustrate my proposals throughout the thesis.
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Chapter 2
Literature review
This chapter provides an overview of the subject. The first section presents a brief de-
scription of radiation, introduces different types of radiation, basic facts regarding radiation
and different trends to study the relationship between ionizing radiation and cancer. We
review the epidemiological studies of low dose levels of ionizing radiation and cancer in the
second section. The final section gives a review of the statistical studies that provide a model
to evaluate the power and sample size for the cohort and case-control studies.
2.1 About ionizing radiation and studies related to cancer
Ionizing radiation is a kind of radiation with high energy that can remove electrons from
atoms and molecules (Canadian Nuclear Safety Commission 2020). There are two general
sources of ionizing radiation (Canadian Nuclear Safety Commission 2020):
1. natural: Space and cosmic radiation, terrestrial radiation, etc.
2. artificial: X-ray, nuclear power plants, etc.
The unit used to measure the amount of ionizing radiation received for each person (usually
per year) is millisievert denoted by mSv (or mSv/y for per year measurements).
Four categories of annual effective doses of ionizing radiation are as follows (Fazel et al.
2009):
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1. low: Doses between 0 mSv/y and 3 mSv/y.
2. moderate: Doses between 3 mSv/y and 20 mSv/y.
3. high: Doses between 20 mSv/y and 50 mSv/y.
4. very high: Doses over 50 mSv/y.
Notice that doses below a specific threshold (usually 0.1 or 0.2 mSv/y) are recorded as 0.
Ionizing radiation-Cancer studies can be divided into two general categories:
1. The oldest and the most studied category is related to the low dose levels of ionizing
radiation (presented with details in the following section).
2. A relatively new study deals with high dose levels of ionizing radiation which, for
instance, studies long term radiology survivors.
In the following section, I review studies of the first type.
2.2 Epidemiological studies of low dose levels of ionizing radiation
Low dose levels of ionizing radiation-cancer studies are followed in 3 general trends:
1. studies based on the atomic bomb event.
2. other ionizing radiation-cancer studies:
(a) based on background ionizing radiation
(b) based on occupational ionizing radiation.
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2.2.1 Studies based on atomic bomb event
Since the early days, the survivors of the atomic bomb in Hiroshima and Nagasaki have
been the main subjects of cancer and ionizing radiation studies. Studies based on these
subjects has provided remarkable results. Contributions based on this study continue to
come out.
The first study related to the impact of ionizing radiation on the mortality and incidence
of cancer dates to 1950 when the Atomic Bomb Casualty Commission (ABCC) started
studying a fixed cohort of A-bomb survivors and suitable comparison subjects (as a non-
exposed group). ABCC was established to investigate the health effects of atomic bombs
in Hiroshima in 1947 and Nagasaki in 1948 by the US National Academy of Science and
the National Research Council. The sample known as the Life Span Study (LSS) sample
was later followed up by the successor of ABCC, the Radiation Effects Research Foundation
(RERF) which substituted ABCC in 1975. The RERF cohort now includes the atomic bomb
survivors (LSS), a cohort of those who were exposed in their mother’s womb (in utter) and a
cohort including the children of survivors who were conceived after paternal exposure (F1).
The results are regularly updated and published. The first results of this series were
published in 1962 (Beebe et al. 1962). The study is based on the LSS cohort. One major
finding of these studies was that an excess incidence of leukemia was observed while for other
cancers (as a whole), the results were insignificant. Similar results persisted to show in future
studies suggesting that leukemia should be the main focus of the study. This direction is
still followed in ionizing radiation-cancer studies: Most studies consider leukemia separately.
The first study to publish results in this area is Beebe et al. (1962). This study is based
on the follow-up of the LSS cohort from 1950 to 1958. The main results of this study are
presented in Beebe et al. (1962; Table IX). This table shows that the p-value for the relative
risk for leukemia is less than .01 while it is non-significant for that of other cancers.
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Remark 2.1. One important point regarding this study is that the sample size has been
relatively small at the time the study was carried out. Sampling which was based on sampling
distance from the point where the bombs were detonated has been explained with details
in the aforementioned reference. The sample size problem has also been addressed there.
In the following years, more subjects were included and the sample size gradually grew. As
explained before, a result of the smallness of the sample size is low power. Therefore, the
non-significant p-value for ”other cancer” in this study “ might” reflect not the truth but it
could be a result of low power to detect an effect.
The results for the LSS study for the period of 1950-1985 are provided in Shimizu et al.
(1990). There are 75, 991 eligible individuals included in this study (referred to as DS86) of
which 5, 936 individuals in the cohort died of cancer. Shimizu et al. (1990; Table II) presents
the results of this study. Notice that the results of this study for leukemia alone, all cancers
and all cancers except leukemia are all significant.
Remark 2.2. Table II in Shimizu et al. (1990), in particular, shows a very strong relationship
between all cancers and radiation. As presented above, the very early study covering the
period of 1950-1958 was unable to detect such an effect. It should be mentioned that the
total number of deaths from all cancers at the time this study was carried out was 199
(compared with 5, 936 deaths in the latter study). This observation “could” be a result of
the difference between the powers in the two studies. This can emphasize the importance of
taking the power into account before interpreting the results of any study.
Table 2 in Ozasa et al. (2019) provides the results for the cancer mortality and incidence
rate based on the most recent studies of the LSS cohort. Notice that all the results show a
positive ERR/Gy both for incidence and mortality for a full range of doses.
Remark 2.3. Notice that the part of Ozasa et al. (2019; Table 2) representing ‘Lowest dose
range with significant risk “can” give some indication of increase in the statistical power
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with increase in the number of years of follow-up: For the incidence report, the evidence can
clearly support this idea as the lowest effective dose has fallen from .15 Gy in 2007 to .10
Gy in 2015 and simultaneously the significance level has been reduced from .1 to .038. The
results for mortality are not nearly as clear. The lowest effective dose has increased from .12
Gy in 2003 to .2 in 2012. However the fact that the significance level has been reduced from
.1 to .05 should be taken into account.
2.2.2 Other ionizing radiation-cancer studies
The results of the atomic bomb studies rose the question of whether other sources of
ionizing radiation are carcinogen. These studies can generally be divided into two types:
1. Natural background ionizing radiation studies
2. Occupational ionizing radiation studies
Natural background ionizing radiation studies
Background ionizing radiation is a source of radiation which has always been present in
the environment (UN committee 2000). Based on United Nations report (UN committee
2000; Annex B), there are four major sources of natural ionizing radiation:
1. cosmic radiation (such as radiation emitted by the sun)
2. terrestrial radiation (such as radiation caused by the natural deposits of uranium)
3. radionuclides present in the air
4. radionuclides present in the food
Although published results in this area mostly support the harmful effects of ionizing radia-
tion on the incidence of cancer, some studies favor a harmless effect. A review on the papers
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of the first type is provided in Hendry et al. (2009) while Dobrzynski1 et al. (1998) reviews
papers of the second type.
Some studies in this field are based on recruited individuals. However, major studies
rely on national registries. Two important examples of such studies are the US surveillance,
Epidemiological, and End Results (SEER) program (SEER 2009) and studies based on UK
National Registry of Childhood Tumors (UK cancer study 1; 2, Wakeford et al. 2009) present
results based on this database.
Some results on the relationship between ionizing radiation and childhood cancer in Great
Britain based on the aforementioned database are presented in UK cancer study (1). The
main results of this study are shown in UK cancer study (1; Table3).
Remark 2.4. Table 3 in UK cancer study (1) shows that the results for all dose categories
are insignificant. This could be a reflection of truth or a result of low power. This paper has
been evaluated in Little et al. (2010) in terms of power. It is shown there that the relatively
small number of cases and controls results in a low power to detect the true effect. Therefore,
the insignificant results of the paper are not surprising and should be expected due to low
power.
Occupational ionizing radiation
Some occupations inevitably require exposure to higher-level doses of radiation than
that of the general public. The most important of such occupations are related to nuclear
power plants, uranium mines, health care units. Workers in each of these fields are not only
exposed to the background ionizing radiation but also exposed to radiation-related to their
profession. As a result, studies of mortality and morbidity of such occupations can provide
some insight into the nature of the relationship between ionizing radiation and cancer. Such
studies usually rely on national databases.
One of the oldest and largest of such databases is Canada’s National Dose Registry (NDR
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website 2020). NDR was founded in 1951 and has continually been in operation thereafter.
This is the largest national database on occupational radiation. NDR contains the records
of more than half a million workers of which 150, 000 are the present-day workforce (NDR
website 2020).
Ashmore et al. (1998) published in 1998 is the first large scale mortality study based
on the National Dose Registry of Canada. This study inspects the database for the period
of 1951-1983. The study cohort consists of 256, 425 individuals. The results are presented
both in terms of standardized mortality rate (SMR)which is based on comparing the death
results with the general population of Canada and also in terms of Excess relative risk (ERR)
which is based on comparing the exposed groups with the non-exposed group in the cohort.
The results of these two measurements are contradictory! Results for the SMR show lower
death risk for the cohort while ERR results prove something in contrast to that of SMR as
the relative risk for the exposed groups is higher than that of the non-exposed group. This
feature, less and more, shows in other occupational studies. It is widely believed that SMR
is not a good measurement for occupational studies as the truth is masked by the so-called
‘healthy worker effect’.
When each cancer is considered independently, the ERR results of the aforementioned
study are mostly insignificant. However, for all cancers as a whole ERR is significantly non-
zero. Table 7 in Ashmore et al. (1998) and Table 8 in Ashmore et al. (1998) (for males and
females, respectively) presents the results of this study.
Remark 2.5. Significant results for ‘all cancers’ in Ashmore et al. (1998; Tables 7 and 8)
could be a result of enough power due to a sufficient number of cancers as a whole while
breaking down cancers into specific types reduces the number of cases and lowers the power.
Therefore, insignificant results for each type of cancer independently “might” be attributable
to low power.
Although NDR studies that include all types of radiation workers are few, there are more
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studies solely based on nuclear workers in NDR. These types of studies started earlier with
Gribbin et al. (1993) having been published in 1993. These studies are naturally based on
fewer observations. The said study included only 8, 977 individuals. The results of this study
even for solid cancer (i.e. all cancers as a unit) was insignificant. Zablotska et al. (2014) is a
more recent study of this type published in 2013. The results of this study for solid cancer
were still non-significant.
Remark 2.6. Comparison of the earlier NDR study reviewed above with the latter two studies
“could” again emphasize the role of power as the first study that included a much larger
dataset was able to detect a significant result for solid cancer while the last two which are
based on smaller databases didn’t detect any significant effect.
2.3 Power studies of the cohort and case-control designs
The results of a statistical test could turn out to be insignificant due to several reasons.
One possibility is that the result truly reveals the real nature of the relationship, i.e. the
exposure is not related to the outcome. However, it can also be a result of some defect in
the study. Such a defect might be related to some sort of bias in the study design or due to
low power which in turn can be attributed to an insufficient number of participants in the
study.
There are a couple of works in the literature that try to address the latter problem of
power, particularly for cohort and case-control studies. I focus on the cohort and case-control
studies as the majority of studies in the area of ionizing radiation-cancer are of these types.
The results of one of the earliest studies to address the problem of power and sample
size both for cohort and case-control studies were published in Schlesselman (1974). The
paper deals with the simplest type of epidemiological studies where the relationship between
the disease status and a binary exposure is of interest. Although the study is general, it
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specifically solves the power/sample size problem for an epidemiological study that tries to
answer the question of whether there is an increased risk of giving birth to a child with a
congenital heart defect (CHD) among mothers who have oral contraceptive (OC) exposure
three months before or after conception.
The formula provided power and sample size in the said reference is based on a simple
assumption of the normal distribution for RR and OR in cohort and case-control studies
respectively. The results showed that a case-control study is more powerful in detecting
CHD/OC relationship.
In most case-control and cohort studies usually, more complex conditions result in the
need for models that are more complicated to find the statistical power. The most natural
problem that can be posed after handling discrete exposures is how to deal with continuous
exposures. The simplest approach is to dichotomize the exposure to use the discrete formula.
However, as noted in Lubin et al. (1990), since the risk patterns might be monotonic with
increasing exposure, an explicit category of ‘not exposed’ might be not meaningful. Also,
this approach has been proven to overestimate the required sample size (and equivalently
underestimate the power)(Lubin et al. 1990).
Mckeown-eyssen and Thomas (1985) is one of the earliest papers to address the problem
of continuous exposure. The paper considers case-control studies and proposes the idea of
comparing the mean of exposure between cases and controls to test any effect of the exposure.
Based on this idea the formula for power and sample size is provided. In particular, the
following formula is given for the sample size,
n =
2(tα − tβ)2σ2
(µ1 − µ0)2
where t stands for the t-distribution, α and 1 − β denote the level of the test and desired
power respectively, σ2 denotes variance of exposure and µ0 and µ1 is the mean of the exposure
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in cases and controls. The paper also explains an apparent paradox in this formula: The
formula suggests that smaller variability in exposure results in smaller sample size while
epidemiological studies prove something in contrast. The model proposed by this paper has
been specifically applied to cancer and diet problems.
Using a logistic regression model with an exposure x (either continuous or discrete), the
probability of having the disease is given by
p(x;α, θ) =
eα+θx
1 + eα+θx
. (2.1)
This can provide the bases for calculating the power and sample size in a case-control study.
However, in practice more complex conditions may arise which can not be handled well
with this simple approach. A couple of such conditions are addressed in Lubin and Gail
(1988). This reference tries to solve the power/sample size problem based on a fairly unified
method which provides a general framework for all problems simultaneously. The models
are specifically applied to the study of lung cancer risk associated with exposure in the home
to radon-222 and its short progeny. The need to develop new power/sample size models all
arose from this study but, as explained in the said paper, can be applied to any study with
similar problems.
The first problem in this study came from the analysis of underground miners which
showed that the standard exponential trend as in model (2.1) can not explain the true
nature of relationship. Rather, it is well characterized by a linear model. They proposed the
following model
p(x;α, θ) =
r(x)
1 + r(x)
=
eαR(x;α, θ)
1 + eαR(x; θ)
(2.2)
23
where R(x) = 1 + θx. Testing the null hypothesis of no association is then equivalent to
H0 : θ = 0. Based on this model, formulas for power and sample size are provided.
By changing the definition of function R, they also provide the formula to handle a more
complex situation that can not be dealt with using typical models. One such situation arises
when one wishes to test curvilinearity in the trend. For example, there has been evidence
that suggests that the increase in the relative odds of lung cancer from exposure to radon is
not linear over the entire range of exposure. The model which is proposed is based on (2.2)
and the following model based on which power and sample size for such a test are provided
R(x) = (1 + βx)e−θx.
Test for curvilinearity is again H0 : θ = 0.
Other complex circumstances considered in this reference are:
1. Testing whether the gradient is equal to a specified non-zero value.
2. Testing for no effect after adjustment for second risk factor under a multiplicative
model.
3. Testing for an additive joint association for two risk factors under a multiplicative
alternative.
The first power model specifically designed for ionizing radiation-cancer studies is provided
in Little et al. (2010). The model proposed tries to follow the usual traditions which are
considered in epidemiological studies of ionizing radiation-cancer. This includes breaking
the dataset into substrata where each substratum is a combination of age and sex. It also
dichotomizes the ionizing radiation dose variable. The model has been used to detect the
power of ‘background ionizing radiation-childhood leukemia’ studies in Great Britain. Such
epidemiological studies have already been underway for several decades. However, the model
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is fairly general so that it can be deployed in other settings such as ‘Occupational ionizing
radiation-solid cancer’ studies. My research falls under the latter.
The model is obtained based on Monte-Carlo simulation. Age+sex strata are considered
independently. The dose variable is broken down into a few categories. The model makes
two basic assumptions:
1. The dose of ionizing radiation is assumed to have a linear effect on RR (in the cohort)
and OR (in case-control). For example, in the cohort study, it is assumed that
RiskRatio =
Risk for dose category with D
Risk for category unexposed to radiation
= 1 + θD.
2. Fixed number of cases at each age/sex stratum. These numbers are obtained from the
observed dataset.
The number of cases mentioned above serves as the number of trials in a multinomial model.
To produce simulated samples (under both null and alternative), it is assumed that the
number of cases at each age+sex stratum is distributed among dose categories according to
a multinomial distribution the probabilities of which depend on parameter θ. More precisely,
assume that we break down the i-th age+sex stratum into K dose categories. Assume also
that in the observed data set, we have mi j cases (deaths) in the j-th dose category of the i-th
age+sex stratum and that the population proportion of the same category is pi j. Then we
assign a multinomial distribution to this stratum with number of trials given by
Mi =
K∑
j=1
mi j
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and corresponding probabilities calculated as
pii j =
pi j(1 + θDi j)∑K
j=1 pi j(1 + θDi j)
.
The likelihood function and the score test statistic are then calculated based on the indepen-
dent multinomial distributions. Using the Rao’s theorem (Rao 1948), the score test statistic
is assumed to have asymptotic normal distribution under the null which is H0 : θ = 0.
A sample of size 100, 000 is then randomly sampled from the alternative. The power
is then calculated as the proportion of samples rejected. This procedure is repeated for
every year of follow-up and power curves are drawn based on the information for all years of
follow-up.
Results of this study provide two important pieces of information:
1. What is the best study design in terms of power? Figure 1 in Little et al. (2010)
provides an answer to this question. As the graph shows, a cohort study with homoge-
neous ERR gives the largest power for any given year of follow up. Cohort study with
heterogeneous ERR, ecological study and case-control study with 5 controls per case
have slightly smaller power while case-control study with only one control per case has
remarkably smaller power. Figure 2 in Little et al. (2010) presents the comparison
between case-control studies with different numbers of control per case. It was sug-
gested that the optimum number of controls per case is 5: This number is proposed
based on the observation that fewer controls provide remarkably lower power while
more controls don’t significantly improve the power.
2. Some previous epidemiological studies which reported an insignificant result for the
background ionizing radiation-childhood leukemia relationship were evaluated based
on this power study. Many such studies were found to be underpowered. Conse-
quently, the insignificant result of such studies can not reflect the true nature of the
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relationship between ionizing radiation and childhood leukemia. Therefore, they should
be interpreted with caution!
2.4 Conclusion
In this chapter, I gave a brief introduction to ionizing radiation. Sources of ionizing
radiation and studies of ionizing radiation-cancer were reviewed. I also presented an overview
of studies that provide a model to detect the power of cohort and case-control studies.
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Chapter 3
Procedure to calculate the power for the cohort study
In this chapter, I develop the formal procedure which is used to estimate the power of the
cohort design for ionizing radiation-cancer studies. The model which is used to estimate the
power is called the “linear dose-effect” model which is explained with details in the following
section. The procedure has been presented in Little et al. (2010) without details. I bridge
all the gaps in the aforementioned reference. I spot some problems in the procedure and
propose new approaches. As a result, I provide formulas that are slightly different from the
formulas presented in that reference. I use simulated data to demonstrate that my formula
for the power and sample size are more reliable.
I describe the algorithm which is used in Little et al. (2010) to calculate the power based
on a normal-sampling approach: distribution of the score test statistic under null is assumed
normal. The power is then calculated by sampling from the alternative. However, using
simulated data (which is presented in Section 6.3) I realized that the score test statistic
seems not only to be approximately normal under the null but it is also approximately
normal under the alternative. In Corollary 5.1, I show why this seemingly unusual feature
is the case (notice that Rao’s theorem (Rao 1948) only states that the score test statistic is
asymptotically normal under the null).
Similar results will be presented in the next chapter for the case-control studies.
Notice that for both study designs we use the score tests statistics. One could develop
the model based on two other well-known test statistics, i.e. the Wald and the LRT. One
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important advantage of the score statistic against the Wald statistic is that it doesn’t require
the point estimation for the parameter. Regarding the LRT, it is possible to reconstruct the
models proposed in this chapter and the next chapter by replacing score with LRT. All the
basics are the same, only the formula for the test statistic changes. Using the fact that
the LRT is asymptotically normal (just as the score is), all the methods proposed with
the score still work with the LRT. However, our main focus in this research is to improve
th performance of the model proposed in Little et al. (2010) which is based on the score
statistic.
3.1 Development of the procedure
The procedure for my study is developed based on a Monte-Carlo approach. I derive
some basic information about the population under study from the given sample. I assume
that any other possible sample (with the same size) would share some features with the
current sample. The assumption is that after drawing samples, the total number of cases
(deaths) in each stratum of age+sex (e.g., ”males, age 30” or ”females, age 32”) will be the
same as the observed value in our single sample. Variability in the samples, i.e. variation in
the incidence of death from cancer, comes from the distribution of cases among dose groups
at any stratum of sex+age. This variation is determined through multinomial distributions
for any stratum in two steps:
1. The number of trials at each stratum is obtained from the observed sample (denoted
by Mi).
2. I break down each stratum into Ki dose categories. The multinomial probabilities are
then found based on a linear-dose effect model for the risk ratio as discussed below.
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Figure 3.1 illustrates how I break down the dataset into age+sex strata and dose categories.
Each row in this table represents one age+sex stratum. Also, Each column is corresponding
to one dose category (in this table we assume Ki = K for I ≤ i ≤ I). A multinomial
distribution is assigned to each row (strata). In this table, pp stands for the population
proportion of each cell in its row. Notice that
Mi =
K∑
j=1
mi j,
K∑
j=1
pi j = 1 1 ≤ i ≤ I.
Figure 3.1: Break-down of dataset into age+sex strata and dose categories
Let i ∈ I be the index for some stratum of age+sex, and let Di j for j ∈ Ki denote the
average dose of some dose category in the i-th stratum. As mentioned above we would like
to find the probability that some cases (whether incidence or death) in stratum i falls in
category j of dose. To link probabilities of multinomial distributions to the excess relative
risk, we use a linear dose-effect model for the risk ratio which is very common in the literature
(See in particular BEIR V (1990)). Then, we will be able to derive the likelihood function
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for the ERR parameter. The linear dose-effect model is defined as follows:
Risk Ratio for category ij = probability of being a case in the dose category i j (mean dose=Di j)probability of being a case in the non-exposed category (Dose=0)
=
P(case − i j)
P(case − nonexposed)
= 1 + θiDi j. (3.1)
This model is used to extract information regarding the probabilities of the multinomial
distribution. Consequently, we can insert our desired parameters in the likelihood function.
In this formula, “case-non exposed ” means a case of cancer (either incidence or mortality,
depending on study) int the non-exposed group. Notice that at this stage, for sake of
generality, we assume that each stratum i has its specific ERR parameter θi. In practice, we
usually assume one parameter for all strata.
The linear dose-effect model is one of the two common models used in the study of
ionizing radiation and cancer, the other being the quadrative dose-effect model (BEIR V
1990). It has been proposed in (BEIR V 1990) that for low dose levels of ionizing radiation,
the linear dose-effect model works well enough. So, we stick to this simpler model. Using
equation (3.1) we proceed to find the probabilities of the multinomial distribution described
above.
Remark 3.1. It should be mentioned that the main reference in which this procedure has
been developed (Little et al. 2010) derives the formula for the probabilities of multinomial
distributions using a different approach than what we present below. Actually, to derive the
said formula they assume that pi j(1 + θiDi j) is cancer risk where pi j denotes the proportion
of the population of stratum i which falls in category i j of dose. However, I prefer not to
make this assumption as it seems that there is no evidence why the above value should fall
between 0 and 1 (Notice that risk is a probability and should be between 0 and 1).
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Using equation (3.1) we can write
P(case − i j) = P(case-non exposed)(1 + θiDi j). (3.2)
On the other hand,
P(case − i j) = Number o f cases in categoryi j
size o f i j
=
Mi j
pi jTi
. (3.3)
where pi j is as defined above, Ti denotes the total population of stratum i and Mi j is the
number of cases in category i j of dose. Now combining equations (3.2) and (3.3) we get
Mi j = pi jTiP(case non − exposed)(1 + θiDi j).
As a result total number of cases in stratum i is given by,
Mi =
Ki∑
j=1
Mi j
=
Ki∑
j=1
pi jTiP(case non − exposed)(1 + θiDi j)
Now, we can provide pii j’s, the probabilities of multinomial distribution at each stratum i.
As mentioned above, pii j is probability that a case in stratum i falls in category j of dose. It
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is given by
pii j =
Mi j
Mi
=
pi jTiP(case non − exposed)(1 + θiDi j)∑Ki
j=1 pi jTiP(case − non exposed)(1 + θiDi j)
=
pi j(1 + θiDi j)∑Ki
j=1 pi j(1 + θiDi j)
. (3.4)
Notice that in equation (3.4) if we set θi = 0, then using the fact that
∑Ki
j=1 pi j = 1, we would
get pii j = pi j. This is natural as when there is no relationship between the exposure and
outcome, the number of cases at each category is only proportional to the size (population)
of the category.
Now, we are ready to provide formula for the Likelihood function. First of all notice that
samples are drawn independently. Therefore, the general Likelihood function is given by
L =
∏I
i=1 Li where li denotes the Likelihood function for stratum i. To calculate the formula
for li notice that samples in stratum i are assumed to occur according to a multinomial
distribution with Mi trials and probabilities (pii j)Kij=1 given by equation (3.4). Therefore, if we
assume that mi j is the variable representing number of cases in category i j, then we will have
Li(θi|(mi j)Kij=1) =
Mi!∏Ki
j=1 mi j!
Ki∏
j=1
pi
mi j
i j
Therefore,
L((θi)Ii=1|((mi j)Kij=1)Ii=1) =
I∏
i=1
Li(θi|(mi j)Kij=1)
=
 I∏
i=1
Mi!∏Ki
j=1 mi j!

 I∏
i=1
Ki∏
j=1
 pi j(1 + θiDi j)∑Ki
j=1 pi j(1 + θiDi j)

mi j
Notice that c =∏Ii=1 Mi!∏Ki
j=1 mi j!
does not depend on θi and is a fixed scalar. Now, we can rewrite
33
the above equation as
L((θi)Ii=1|((mi j)Kij=1)Ii=1) = c
I∏
i=1
∏Ki
j=1(pi j(1 + θiDi j))
mi j[∑Ki
j=1 pi j(1 + θiDi j)
]∑Ki
j=1 mi j
.
Finally, using the fact that ∑Kij=1 mi j = Mi, we can write
L((θi)Ii=1|((mi j)Kij=1)Ii=1) = c
I∏
i=1
∏Ki
j=1(pi j(1 + θiDi j))
mi j
[
∑Ki
j=1 pi j(1 + θiDi j)]
Mi
.
Now, the log-Likelihood function is given by
l = l((θi)Ii=1|((mi j)Kij=1)Ii=1)
= log(l((θi)Ii=1|((mi j)Kij=1)Ii=1))
= c′ +
I∑
i=1
{ Ki∑
j=1
mi jln[pi j(1 + θiDi j)]
− Miln[pi j(1 + θiDi j)]
}
. (3.5)
So far we have assumed that each strata might have a different ERR parameter θi. Now, we
assume that this parameter is the same for all strata. So, let θi = θ for all i ∈ I. Carrying
this fact in mind and using equation (3.5) we obtain the formula of the score test statistic,
dl
dθ
=
I∑
i=1
 Ki∑
j=1
mi jDi j
1 + θDi j
− Mi
∑Ki
j=1 pi jDi j∑Ki
j=1 pi j(1 + θDi j)
 (3.6)
As explained in the first chapter, the score test statistic is usually defied as (dL
dθ
)2/var(
dL
dθ
)
which has asymptotic chi-squared distribution. Since, we have only one unknown variable,
the score test statistic has asymptotic chi-squared distribution with one degree of freedom
under the null hypothesis. Using the fact that the square root of χ21 is normal, we prefer to
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work with dL
dθ
/(var(
dL
dθ
))1/2.
The goal of my research is to find the power to detect a true effect. An effect here is equivalent
to a non-zero ERR value θ1 , 0. Therefore, our hypothesis test should be H0 : θ = 0. Then
we need to check how often we truly reject H0 in favor of H1 : θ , 0 when the samples
come from the true value θ1. So, we need to calculate the score statistic under θ = 0. Using
equation (3.6) this is given by
dL
dθ
|θ=0 =
I∑
i=1
 Ki∑
j=1
mi jDi j − Mi
Ki∑
j=1
pi jDi j
 . (3.7)
As explained in the first chapter, in order to obtain a closed-form formula for the power
(in particular to calculate a formula for the sample size) we need to know a theoretical
distribution for the score test under the null both when samples come from θ = 0 and when
they come from another desired value such as θ1 which we wish to be able to detect. As
described there, under the null the standardized score test has χ21 distribution (or equivalently
its square root has a normal distribution) provided that sample size is large enough. However,
under θ1 , 0 this might be not true. Actually, this is one reason why Little et al. (2010)
chooses a sampling approach under θ1 side to calculate the power.
The aforementioned reference needs to assume a normal distribution for the score test
under the null when samples come from θ1 too. In the following section, we will prove
a theorem showing that in this specific study the score test under the null when samples
come from θ1 is as good normally distributed as it is when samples come from θ = 0. As
a result, we will be able to theoretically prove that the closed form-formula for the power
is nearly as reliable as the sampling approach. Also, the sample size formula will find a
stronger foundation. I use a different formula than the one provided in Little et al. (2010)
to calculate the power closed-form formula and the sample size. Simulation studies that are
presented in Appendix A show that my formula provides power estimates which are closer
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to power estimates from the Monte-Carlo method.
We need to find the mean and the variance of score test statistic under the null when
samples come from some parameter θ. Using equation (3.7) we can write
Eθ[
dl
dθ
|θ=0] =
I∑
i=1
 Ki∑
j=1
Eθ[mi j]Di j − Mi
Ki∑
j=1
pi jDi j
 . (3.8)
It should be pointed out that from now on an explicit subscript θ = 0 means that the
parameter is equal to 0 while a general parameter θ (such as in Eθ below) means that the
parameter could be any arbitrary value (possibly non-zero). Notice that each mi j is a binomial
variable with n = Mi trials and
p = pii j =
pi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)
success rate. Therefore, its mean is given by
Eθ[mi j] = np = Mipii j
= Mi
pi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)
. (3.9)
Putting equations (3.8) and (3.9) we get
Eθ[
dl
dθ
|θ=0] =
I∑
i=1
 Ki∑
j=1
Mi
pi j(1 + θDi j)Di j∑Ki
j=1 pi j(1 + θDi j)
− Mi
Ki∑
j=1
pi jDi j

=
I∑
i=1
Mi

∑Ki
j=1 pi j(1 + θDi j)Di j∑Ki
j=1 pi j(1 + θDi j)
−
Ki∑
j=1
pi jDi j

= θ
I∑
i=1
Mi

∑Ki
j=1 pi jD
2
i j − [
∑Ki
j=1 pi jDi j]
2
1 + θ
∑Ki
j=1 pi jDi j
 . (3.10)
Variance of the score test under the null when samples come from some θ can also be
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calculated using the formula
varθ[
dl
dθ
|θ=0] = cov( dldθ |θ=0,
dl
dθ
|θ=0)
= cov(
I∑
i=1
Ki∑
j=1
mi jDi j,
I∑
i=1
Ki∑
j=1
mi jDi j) (3.11)
Notice that for i and i′ ∈ I all mi j variables are independent from all mi′ j′ variables. Also,
using properties of binomial variables, each mi j has variance
var[mi j] = np(1 − p) = Mipii j(1 − pii j)
= Mi
pi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)
1 − pi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)
 . (3.12)
In addition, using properties of multinomial distribution, the covariance between two vari-
ables mi j and mi j′ is given by
cov(mi j,mi j′) = −Mipii jpii j′ .
Putting all this facts together and using equation (3.11) we can write
varθ[
dl
dθ
|θ=0] =
I∑
i=1
cov(
Ki∑
j=1
mi jDi j,
Ki∑
j=1
mi jDi j)
=
I∑
i=1
 Ki∑
j=1
[
D2i jvarθ[mi j]
]
+ 2
∑
1≤ j′< j≤Ki
[
Di jDi j′cov(mi j,mi j′)
]
=
I∑
i=1
Mi
{ Ki∑
j=1
D2i j pi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)
1 − pi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)


− 2
∑
1≤ j′< j≤Ki
Di jDi j′ pi jpi j′(1 + θDi j)(1 + θDi j′)(∑Ki
j=1 pi j(1 + θDi j)
)2

}
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=I∑
i=1
Mi

∑Ki
j=1 D
2
i jpi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)
−

∑Ki
j=1 Di jpi j(1 + θDi j)∑Ki
j=1 pi j(1 + θDi j)

2
=
I∑
i=1
Mi

[∑Ki
j=1 D
2
i jpi j + θ
∑Ki
j=1 D
3
i jpi j
] [
1 + θ
∑Ki
j=1 pi jDi j
]
−
[∑Ki
j=1 Di jpi j + θ
∑Ki
j=1 D
2
i jpi j
]2[
1 + θ
∑Ki
j=1 pi jDi j
]2
 .
(3.13)
Now let
µθ = E[
dl
dθ
|θ=0] , σθ =
√
varθ[
dl
dθ
|θ=0].
Then,the distribution of the score test statistic under an arbitrary parameter θ is normal
Z(µθ, σ2θ).
Next, we proceed to calculate a closed-form formula for power.
Remark 3.2. At this point, it should be pointed out that in the main reference (Little et al.
2010), the closed-form formula for provided for the power seems to be inappropriate. The
reason is that one has to notice the difference between the variance of the score statistic under
null and alternative. In many statistical studies of power the variance of test statistic under
both null and alternative are equal. Therefore, in order to obtain the power they usually
start from the standardized score statistic under null (i.e. score test divided by the SE under
null). The results remain valid as the score statistic under the alternative is automatically
standardized as well. However, equation (3.13) shows that in my study the variance (hence,
SE) under null and alternative are unequal. Therefore, starting from standardized score
statistic leads to inappropriate formula for power. This is what Little et al. (2010) does. In
the sequel I take the a different approach and provide a different formula. In Section 6.5 I
will use some simulated data to compare the power based on the closed-form formula given
in Little et al. (2010) and closed-form formula proposed here. We will see that my formula
provides results very close to the power result from the sampling method while results from
the formula given in Little et al. (2010) are not close enough to the sampling values and
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sometimes they are even completely irrelevant.
Notice that we need to calculate the distribution of score statistic under null H0 : θ = 0.
Using formulas (3.13) and (3.10) we can see that
Eθ=0[
dl
dθ
|θ=0] = 0.
Also we have
varθ=0[
dl
dθ
|θ=0] =
I∑
i=1
Mi
{ Ki∑
j=1
[
D2i jpi j(1 − pi j)
]
− 2
∑
1≤ j′< j≤Ki
[
Di jDi j′ pi jpi j′
] }
. (3.14)
Let σ0 =
√
varθ=0[
dl
dθ
|θ=0], then score statistic under θ = 0 is Z(0, σ20).
Remark 3.3. To calculate the power we can take samples from alternative and assume a
normal distribution for the score statistic under null. The formula for the score statistic
under null is
Z =
dl
dθ
|θ=0
/√
varθ=0[
dL
dθ
|θ=0]. (3.15)
As this equation shows the variance in the denominator is the variance under null (as rep-
resented by subscript θ = 0 in the variance). However, in Little et al. (2010) the variance
under alternative is included which seems to be inappropriate in case one wishes to assume
a standard normal distribution for the score statistic under the null. Table 1 and Table 2
in Little et al. (2010) show that the said reference assumes a standard normal distribution
under null. Therefore, the variance in the normalized score statistic should be the one under
the null. Using simulated data, I can show that if we use the formula proposed in Little et al.
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(2010), then the distribution of the score test statistic under null is not standard normal. In
Section 6.4, simulated data has been used to show that the score test under null is very well
normal when we use equation (3.15) while it is not nearly as good when we use the formula
proposed in Little et al. (2010).
To calculate the power assume that we have a test with significance level α. Also assume
that, we would like to be able to detect an effect of size θ1. The power of such a test is given
by
P = P(Score test under θ1 > Qα)
= 1 − P(N(µθ, σ2θ) < Qα) (3.16)
where Qα is the %100(1 − α) quantile of the test statistic under null. In other words, we
must have
1 − α = P(Score test under θ0 < Qα)
= P(N(0, σ20) < Qα)
= P(N(0, 1) <
Qα
σ0
).
Hence, Z1−α = Qασ0 or equivalently,
Qα = σ0Z1−α (3.17)
where Z1−α is the %100(1−α) quantile of the standard normal distribution. Using equations
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(3.16) and (3.17) we can provide a closed-form formula for the power:
P = 1 − P(N(µθ, σ2θ) < Qα)
= 1 − P(N(0, 1) < σ0Z1−α − µθ
σθ
). (3.18)
Notice that, by contrast, the formula given in Little et al. (2010) is
P = 1 − P(N(0, 1) < Z1−α − µθ
σθ
). (3.19)
3.1.1 Formula for the sample size
Using formula (3.18) and under certain conditions, we are able to calculate the sample
size in order to have tests with a desired power P. For this purpose we need to consider a
single stratum. The reason is that we need to plug equation (3.13) in equation (3.18) and
then solve it for the number of cases Mi, i ∈ I. However, if I > 1 we can not solve this
equation strictly. Therefore, we need to assume I = 1.
Remark 3.4. Formula of the sample size is derived from the formula of the power. Since Little
et al. (2010) provides a different formula for power, their formula for sample size which is
based on equation (3.19) is different too. We use equation (3.18) to provide a different
formula. In Section 6.6 we use some simulated data to compare the sample size derived from
both formulas.
Let I = 1, M1 = M and K1 = K. Then, from equation (3.18) we can write
1 − P = P(N(0, 1) < σ0Z1−α − µθ
σθ
).
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Therefore,
Z1−p =
σ0Z1−α − µθ
σθ
(3.20)
where Z1−P is the %100(1 − P) quantile of the normal standard distribution. Let Z0 = µθσθ .
Then, by equation (3.20) we have
Z0 = (
σ0
σθ
)Z1−α − Z1−P (3.21)
Notice that using equations (3.10) and (3.13) we can derive the following formula for Z0,
Z0 =
θMF1√
MF2
(3.22)
where
F1 =
∑K
j=1 p jD
2
j −
(∑K
j=1 p jD j
)2∑K
j=1 p j(1 + θDi j)
(3.23)
and
F2 =
∑K
j=1
{
D2j p j(1 + θD j)
([∑K
n=1 pn(1 + θDn)
]
− p j(1 + θD j)
)}
− 2 ∑
1≤ j′< j≤K
p jp j′(1 + θD j)(1 + θD j′)[∑K
j=1 p j(1 + θD j)
]2
(3.24)
Using equations (3.21) and (3.22) we infer that
θ
√
M
F1√
F2
=
σ0
σθ
Z1−α − Z1−P
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Therefore,
θ2M
F21
F2
= (
σ0
σθ
Z1−α − Z1−P)2
which implies
M =
F2
θ2F21
(
σ0
σθ
Z1−α − Z1−P)2
=
∑K
j=1
{
D2j p j(1 + θD j)
([∑K
n=1 pn(1 + θDn)
]
− p j(1 + θD j)
)}
− 2 ∑
1≤ j′< j≤K
p jp j′(1 + θD j)(1 + θD j′)
θ2
[∑K
j=1 p jD
2
j −
(∑K
j=1 p jD j
)2]2
× (σ0
σθ
Z1−α − Z1−P)2.
3.1.2 Sampling algorithm to calculate the power for the cohort study
Now that we have derived the formula for the score test statistic, we can design the
sampling procedure to find the power for my study. The objective is to evaluate the power
of the cohort study based on the years of follow up. The general algorithm is as follows:
• Step 0. Fix the effect size to be detected, i.e. fix parameter θ.
• Step 1. Fix number of years of follow-up.
• Step 2. Break down the dataset into I strata and each stratum into J cells. Strata I
is defined as a combination of year (single years) and sex. Cells are defined as dose
categories. Dose categories are defined according to the conventional method in the
literature.
• Step 3. Obtain required information from the dataset (NDR). This includes the fol-
lowing information:
1. Mi for i ∈ I: Number of cases (incidence or death) in stratum i.
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2. Di j for i ∈ I and j ∈ J: Average dose in cell j of stratum i
3. pi j for i ∈ I and j ∈ J: Proportion of the population of cell i j in stratum i.
• Step 4. Sampling:
– Step 4-1. Fix i ∈ I and draw a sample from a multinomial distribution with Mi
trials and J possible outcomes each with probability
pii j =
pi j(1 + θiDi j)∑Ki
j=1 pi j(1 + θiDi j)
.
– Step 4-2. Repeat Step 4-1 for all i ∈ I. Then using formula (3.15) calculate the
value of the test statistic for this sample.
– Step 4-3. Check whether the value from Step 4-2 is greater than Z1−α (where α is
the level of the test, usually α = .05). If so, we mark this trial as a success.
• Step 5. Repeat Step 4 , 100, 000 times. The power is then calculated using the formula
power =
# of successful trials
100, 000
where successful trial is defined in Step 4-3.
• Step 6. Return to Step 1 and choose another number of years of follow up.
• Step 7. If a different effect size is also of interest , return to Step 0 and change θ.
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Chapter 4
Procedure to calculate the power for the case-control study
This chapter is the counterpart of Chapter 3 for the case-control study. This is designed,
less and more, in the same way, that Chapter 3 was done. Again, a linear dose-effect model
is used to estimate the power (see the following section). I explain, with all the details, the
procedure which has been presented in Little et al. (2010). I bridge all the gaps and spot
some problems in the procedure and provide substitute approaches. Similar to the cohort
study I provide new formulas and use simulated data to prove that our formulas for the
power and sample size are more reliable.
I describe the algorithm to calculate the power using a normal-sampling approach. Simu-
lated data which appears in Section 6.3 show that the score test statistic for the case-control
study is approximately normal under both null and alternative. This is a result of Corollary
5.2.
4.1 Development of the procedure
As mentioned in the first chapter, the measure of association in case-control studies is
the odds ratio which compares the status of exposure in cases and controls. In our study,
exposure is defined as ‘being exposed to some level of radiation dose’. Therefore, in the
case-control study levels of dose are of direct interest. So, we assume that there are ND + 1
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dose groups 0, 1, · · · ,ND with associated doses
D0 < D1 < · · · < DND .
The dose categories are defined in the conventional way as used in the epidemiological studies.
For simplicity, at this stage we implement the case-control studies for each case indepen-
dently. Later, we will put together cases which share similar characteristic in terms of age
and sex. Let’s assume that there are S cases. For each case i, we assign Ki controls. So, we
have S independent case-control studies each with 1 case and Ki controls. For study i ∈ S
we define (Pd1i)NDd=0 to be probability that the case falls in groups d of dose. Similarly, assume
that (Pd0i)NDd=0 represents probabilities for controls corresponding to case i. By definition
Odds ratio = P(case exposed)/P(case non-exposed)P(control exposed)/P(control non-exposed) .
So, as long as we are concerned with level d of dose, the odds ratio in the case-control study
i denoted by λd given by
λd =
Pd1i/P01i
Pd0i/P00i
. (4.1)
Here by exposure we mean being exposed to level d of dose. At this point, two fact should
be emphasized:
1. As presented in the first chapter, for studies with low incidence rate (such as cancer),
odds ratio and risk ratio are approximately equal. As a result, if we apply a linear-dose
effect model as proposed in BEIR V (1990), we can still apply the excess relative risk
parameter θ for the case-control studies. Therefore, we must have
λd = λd(θ) = 1 + θd. (4.2)
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2. The power procedure for the case-control study is more complex than that for the
cohort study in several aspects. One reason, as evident in equation (4.1), is that we
have 4 unknown parameters while we want to reduce our problem to a single parameter
θ. We do this step by step. The first step is to apply equation (4.1) to write
Pd1i =
P01i
P00i
Pd0iλd. (4.3)
Using this equation and the fact that ∑NDd=0 Pd1i = 1, we can write
ND∑
d=0
Pd1i =
ND∑
d=0
P01i
P00i
Pd0iλd
=
P01i
P00i
ND∑
d=0
Pd0iλd = 1.
Therefore, we should have
P01i
P00i
=
1∑ND
d=0 Pd0iλd
. (4.4)
Putting equations (4.3) and (4.4) together we conclude that
Pd1i =
Pd0iλd∑ND
d=0 Pd0iλd
. (4.5)
Notice that cases and controls are chosen independently (this is an ordinary case-control
study not a matched one). Also, each case and each control can belong to D+1 dose groups.
Therefore, for each i ∈ I we have two binomial distributions:
• For case: With 1 trial and probabilities (Pd1i)Ii=1.
• For controls: With Ki trials and probabilities (Pd0i)Ii=1.
Let (nd0i)NDd=0 and (nd1i)NDd=0 denote the number of controls and cases in these multinomial
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distributions that belong to group d of dose. So,
ND∑
d=0
nd1i = 1 ,
ND∑
d=0
nd1i = Ki. (4.6)
Since the corresponding multinomial distribution for cases has only one trial, its probability
distribution is given by
P(n01i, · · · , nd1i|(Pd1i)NDd=0) =
ND∏
d=0
Pnd1id1i .
Similarly, for controls the corresponding probability distribution is
P(n00i, · · · , nd0i|(Pd0i)NDd=0) =
ND∏
d=0
Pnd0id0i
Ki!∏ND
d=0 nd0i!
.
Finally, since the I sets of case-controls are independent and in each case-control set, cases
and controls are chosen independently, we see that the likelihood function is given by
L = L(θ, (Pd0i)
ND
d=0, (Pd1i)
ND
d=0|(nd0i)NDd=0, (nd1i)NDd=0)
=
S∏
i=1
 ND∏
d=0
Pnd1id1i
ND∏
d=0
Pnd0id0i
Ki!∏ND
d=0 nd0i!
 . (4.7)
If we replace Pd1i in equation (4.7) by the value given in equation (4.3) we can remove (Pd0i)NDd=0
and write
L = L(θ, (Pd0i)
ND
d=0|(nd0i)NDd=0, (nd1i)NDd=0)
=
S∏
i=1
 ND∏
d=0
 Pd0iλd∑ND
d=0 Pd0iλd
nd1i ND∏
d=0
Pnd0id0i
Ki!∏ND
d=0 nd0i!

=
 ND∏
d=0
λ
S∑
i=1
nd1i
d


S∏
i=1
1(∑ND
d=0 Pd0iλd
)∑ND
d=0 nd1i
ND∏
d=0
Pnd0i+nd1id0i
Ki!∏ND
d=0 nd0i!

=
 ND∏
d=0
(1 + θDd)
S∑
i=1
nd1i
  S∏
i=1
1∑ND
d=0 Pd0i(1 + θDd)
ND∏
d=0
Pnd0i+nd1id0i
Ki!∏ND
d=0 nd0i!
 (4.8)
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where the last equation is written according to the linear-dose effect model as given in
equation (4.2) and the fact that ∑NDd=0 nd1i = 1 . Notice that in equation (4.8) apart from θ,
we have other parameters which are
(
(Pd0i)
ND
d=0
)S
i=1
. Since we just want to test for θ, we need
to remove other parameters by calculating the profile likelihood: We find MLE for all the
parameters other than θ and plug all the MLEs in the likelihood function in order to obtain
the profile likelihood.
To calculate MLE for
(
(Pd0i)
ND
d=0
)S
i=1
notice that Ki , nd0i and Dd are fixed. Also we treat
θ as fixed at this point. Taking a glimpse at the likelihood function given in equation (4.8)
reveals that this function has a nice simple form in that terms for each Pd0i appears as a
multiplicand and there is no interaction between them for any two different values of i. As
a result to maximize the likelihood function with respect to these parameters all we need is
to maximize the functions for each i independently. Therefore, disregarding the fixed terms
we need to maximize each of the following functions
fi(pd0i) =
ND∏
d=0
Pnd0i+nd1id0i
ND∑
d=0
Pd0i(1 + θDd)
, i ∈ I.
We need to solve I equations
∂ fi
∂Pd0i
= 0. (4.9)
We have,
∂ fi
∂Pd0i
=
(nd0i + nd1i)P
nd0i+nd1i−1
d0i
ND∏
d′,d
Pnd′0i+nd′1id′0i
(
ND∑
d′=0
Pd′0i(1 + θDd′)
)
− (1 + θDd)
ND∏
d=0
Pnd0i+nd1id0i(
ND∑
d=0
Pd0i(1 + θDd)
)2 .
49
Plugging in equation (4.9) we get
(1 + θDd)
ND∏
d=0
Pnd0i+nd1id0i = (nd0i + nd1i)P
nd0i+nd1i−1
d0i
ND∏
d′,d
Pnd′0i+nd′1id′0i
 ND∑
d′=0
Pd′0i(1 + θDd′)
 .
Dividing both sides of this equation by
(1 + θDd)P
nd0i+nd1i−1
d0i
ND∏
d′,d
Pnd′0i+nd′1id′0i ,
we find that
Pd0i =
(nd0i + nd1i)
1 + θDd
ND∑
d′=0
Pd′0i(1 + θDd′). (4.10)
Notice that from the multinomial distribution and equation (4.10) we can write,
1 =
ND∑
d=0
Pd0i
=
 ND∑
d=0
(nd0i + nd1i)
1 + θDd
  ND∑
d′=0
Pd′0i(1 + θDd′)

This implies that
ND∑
d′=0
Pd′0i(1 + θDd′) =
1
ND∑
d=0
(nd0i + nd1i)/(1 + θDd)
. (4.11)
Finally, putting equations (4.10) and (4.11) we find the desired MLEs as follows
Pd0i =
(nd0i + nd1i)/(1 + θDd)
ND∑
d′=0
(nd′0i + nd′1i)/(1 + θDd′)
. (4.12)
Now we proceed to find the profile log-likelihood. Notice that in this procedure, all terms
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that do not include parameter θ are assumed fix and we collect them under a generic term
C. First, taking log from equation (4.8), we get
l = ln(L) =
ND∑
d=0

 S∑
i=1
nd1i
 ln((1 + θDd))
 − S∑
i=1
ln
 ND∑
d=0
Pd0i(1 + θDd)

+
ND∑
d=0
(nd0i + nd1i)ln(Pd0i) + ln
 Ki!∏ND
d=0 nd0i!
 . (4.13)
The last term is fixed. Let’s denote it by C. Also, notice that
ND∑
d=0
Pd0i(1 + θDd) =
ND∑
d=0
[nd0i + nd1i]/(1 + θDd)
ND∑
d′=0
[nd′0i + nd′1i]/(1 + θDd′)]
× (1 + θDd)
=
ND∑
d=0
[nd0i + nd1i]
ND∑
d′=0
[nd′0i + nd′1i]/(1 + θDd′)
=
Ki + 1
ND∑
d′=0
[nd′0i + nd′1i]/(1 + θDd′)
.
Therefore,
ln
 ND∑
d=0
Pd0i(1 + θDd)
 = ln(Ki + 1) − ln  ND∑
d′=0
[nd′0i + nd′1i]/(1 + θDd′)
 . (4.14)
Since ln(Ki + 1) is fixed, we will collect it under the generic term C. We can also write:
ln(pd0i) = ln(nd0i + nd1i) − ln(1 + θDd)
− ln(
ND∑
d′=0
[nd′0i + nd′1i]/(1 + θDd′)). (4.15)
Again, we collect ln(nd0i+nd1i) in C. Now plug equations (4.14) and (4.15) in equation (4.13)
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to get
l =
 ND∑
d=0
 S∑
i=1
nd1i
 ln(1 + θDd) + S∑
i=1
ln
 ND∑
d′=0
[nd′0i + nd′1i]/(1 + θDd′)

+
S∑
i=1
ND∑
d=0
(nd0i + nd1i)
−ln(1 + θDd) − ln  ND∑
d′=0
[nd′0i + nd′1i/(1 + θDd′)]
 +C
= −
ND∑
d=0
 S∑
i=1
nd0i
 ln(1 + θDd) − S∑
i=1
ND∑
d=0
nd0iln
 ND∑
d=0
[nd0i + nd1i]/(1 + θDd)
 +C
=
ND∑
d=0
 S∑
i=1
nd0i
 ln(1 + θDd) − S∑
i=1
Kiln
 ND∑
d=0
[nd0i + nd1i]/(1 + θDd)
 +C.
where the last two equations are written using equations (4.6).
Now we can calculate the score test statistic by taking derivative from equation (4.15)
as follows.
S (θ) =
dl
dθ
= −
ND∑
d=0
 S∑
i=1
nd0i
 1(1 + θDd)Dd
+
S∑
i=1
Ki
ND∑
d=0
[nd0i+nd1i]
(1+θDd)2
Dd
ND∑
d=0
[nd0i+nd1i]
(1+θDd)
. (4.16)
To calculate the score test statistic under null we set θ = 0 in equation (4.15). So that we
will get,
S (0) =
dl
dθ
|θ=0
= −
ND∑
d=0
 S∑
i=1
nd0i
Dd + S∑
i=1
Ki
ND∑
d=0
[nd0i + nd1i]Dd
ND∑
d=0
[nd0i + nd1i]
= −
ND∑
d=0
 S∑
i=1
nd0i
Dd + S∑
i=1
Ki
ND∑
d=0
[nd0i + nd1i]Dd
Ki + 1
. (4.17)
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Finally, if in equation (4.17) we collect all terms with nd0i together and all terms with nd1i
together, then we will get
S (0) =
S∑
i=1
ND∑
d=0
[
−1 + Ki
Ki + 1
]
nd0iDd +
S∑
i=1
Ki
Ki + 1
ND∑
d=0
nd1iDd
= −
S∑
i=1
1
Ki + 1
ND∑
d=0
nd0iDd +
S∑
i=1
Ki
Ki + 1
ND∑
d=0
nd1iDd. (4.18)
Similar to the cohort study, we will derive the formula for the variance and expectations in
order to find the normal distribution of the score statistic under null and alternative. For
this purpose notice that for each 1 ≤ i ≤ S and 0 ≤ d ≤ ND, nd0i and nd1i are binomial
distributions with success rates Pd0i and Pd1i and number of trials Ki and 1 respectively.
Also, equation (4.5) shows that
Pd1i =
Pd0i(1 + θDd)
ND∑
d=0
pd0i(1 + θDd)
.
Recall that if X ∼ binomial(n, p), then
E[X] = np , var[X] = np(1 − p).
Therefore, using equation (4.18) we can write
Eθ[
dl
dθ
|θ=0] = −
S∑
i=1
1
Ki + 1
ND∑
d=0
Eθ[nd0i]Dd +
S∑
i=1
Ki
Ki + 1
ND∑
d=0
Eθ[nd1i]Dd
=
S∑
i=1
1
Ki + 1
ND∑
d=0
Kipd0iDd +
S∑
i=1
Ki
Ki + 1
ND∑
d=0
Pd0i(1 + θDd)
ND∑
d=0
pd0i(1 + θDd)
Dd
=
S∑
i=1
Ki
Ki + 1
ND∑
d=0

Pd0i(1 + θDd)
ND∑
d=0
pd0i(1 + θDd)
− pd0i
Dd. (4.19)
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To calculate the variance, note further that all S case-control sets are independent and so
are cases and controls in each set of case-controls. Therefore, in equation (4.18), the only
terms with possibly non-zero covariance are (nd0i)NDd=0 among themselves and (nd1i)NDd=0 among
themselves, for each 1 ≤ i ≤ S .
Recall that the covariance between two marginal binomial distributions X and Y that
come from a multinomial distribution with n trials is −nPXPY where PX and PY are the
success rate for X and Y respectively. Using all this facts and equation (4.18) we can write
varθ(
dl
dθ
|θ=0) = covθ( dldθ |θ=0,
dl
dθ
|θ=0)
=
S∑
i=1
[
1
Ki + 1
]2  ND∑
d=0
varθ(nd0i)D2d − 2
∑
1≤d<d′≤ND
DdDd′cov(nd0i, nd′0i)

+
S∑
i=1
[
Ki
Ki + 1
]2  ND∑
d=0
varθ(nd1i)D2d − 2
∑
1≤d<d′≤ND
DdDd′cov(nd1i, nd′1i)

=
S∑
i=1
1
[Ki + 1]2
 ND∑
d=0
D2dpd0i(1 − pd0i) − 2
∑
1≤d<d′≤ND
DdDd′ pd0ipd′0i

+
S∑
i=1
[
Ki
Ki + 1
]2  ND∑
d=0
D2dpd1i(1 − pd1i) − 2
∑
1≤d<d′≤ND
DdDd′ pd1ipd′1i

=
S∑
i=1
Ki
[Ki + 1]2
 ND∑
d=0
D2dpd0i(1 − pd0i) − 2
∑
1≤d<d′≤ND
DdDd′ pd0ipd′0i

+
S∑
i=1
[
Ki
Ki + 1
]2 [ ND∑
d=0
D2d
Pd0i(1 + θDd)
ND∑
d=0
pd0i(1 + θDd)
1 −
Pd0i(1 + θDd)
ND∑
d=0
pd0i(1 + θDd)

− 2
∑
1≤d<d′≤ND
DdDd′
Pd0ipd′0i(1 + θDd)(1 + θDd′)[
ND∑
d=0
pd0i(1 + θDd)
]2 ]. (4.20)
In particular, if we assign the same number of controls to each case so that for each 1 ≤ i ≤ S ,
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Ki = K and assume that Pd0i = Pd0 and Pd1i = Pd1 , then equation (4.19) can be simplified to
Eθ[
dl
dθ
|θ=0] = S KK + 1
ND∑
d=0

Pd0(1 + θDd)
ND∑
d=0
pd0(1 + θDd)
− Pd0
Dd. (4.21)
Also equation (4.20) can be written as
varθ[
dl
dθ
|θ=0] = S K[K + 1]2
 ND∑
d=0
D2dpd0(1 − pd0) − 2
∑
1≤d<d′≤ND
DdDd′ pd0pd′0

+ S
[ K
K + 1
]2 [ ND∑
d=0
D2d
Pd0(1 + θDd)
ND∑
d=0
pd0(1 + θDd)
1 −
Pd0(1 + θDd)
ND∑
d=0
pd0(1 + θDd)

− 2
∑
1≤d<d′≤ND
DdDd′
Pd0pd′0(1 + θDd)(1 + θDd′)[
ND∑
d=0
pd0(1 + θDd)
]2 ]. (4.22)
So far, we have considered only one general strata. However, similar to the cohort procedure
we would like to break down the dataset into strata of sex and age in order to follow the
convention in the epidemiological studies. So, assume that we have M independent strata
(studies) and implement each study in the way that was just presented. Notice that in this
case the likelihood function can be written as
L =
M∏
m=1
Lm,
where each Lm is the likelihood function of the m-th strata. Therefore, assuming that in all
strata and for each case we assign K controls, the profile log-likelihood using equation (4.18)
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would be
dl
dθ
|θ=0 = dlog(L)dθ |θ=0 =
M∑
m=1
− Sm∑
i=1
1
K + 1
ND,m∑
d=0
nd0imDmd +
Sm∑
i=1
K
K + 1
ND,m∑
d=0
nd1imDmd
 . (4.23)
Here, S m represents total number of cases in stratum m and Dmd represents the average dose
of category d of dose in stratum m. Also, nd0im (nd1im) is total number of controls (cases)
in the i-th case-control set in stratum m that falls in category d of dose. Notice that as
explained
1. nd0im is determined from a multinomial distribution with 1 trial and probabilities given
by
Pd1m =
Pd0m(1 + θDd)
ND∑
d=0
pd0m(1 + θDd)
.
2. nd1im is obtained from a multinomial distribution with K trials and probabilities Pd0m.
We can simplify equation (4.23). Notice that all case-control sets are independent and in each
stratum m, all cases follow similar multinomial distributions and so do controls. Therefore,
by putting terms with common distribution in equation (4.23) we can conclude that
dl
dθ
|θ=0 = dln(L)dθ |θ=0 =
M∑
m=1
− 1K + 1
ND,m∑
d=0
nd0mDmd +
K
K + 1
ND,m∑
d=0
nd1mDmd
 . (4.24)
In this formula nd0m and nd1m are determined as follows
1. nd0m is determined from a multinomial distribution with S m trial (where S m is number
of cases in stratum m) and probabilities given by
Pd1m =
Pd0m(1 + θDd)
ND∑
d=0
pd0m(1 + θDd)
.
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2. nd1m is obtained from a multinomial distribution with KS m trials and probabilities Pd0m.
From equation (4.24) we find the mean of the score statisitc as follows
Eθ[
dl
dθ
|θ=0] =
M∑
m=1
− 1K + 1
ND,m∑
d=0
Kpd0mDmd +
K
K + 1
ND,m∑
d=0
S mKDmdpd1m

=
K
K + 1
M∑
m=1
S m
ND,m∑
d=0

Pd0m(1 + θDd)
ND∑
d=0
pd0m(1 + θDd)
− Pd0m
Dmd. (4.25)
Also, using the same argument as that used to derive equation (4.20), I can propose the
following formula for the variance of this latest model
varθ[
dl
dθ
|θ=0] = K[K + 1]2
M∑
m=1
S m
ND,m∑
d=0
D2mdpd0m(1 − pd0m) − 2
∑
1≤d<d′≤ND
DmdDmd′ pd0mpd′0m

+
[ K
K + 1
]2 M∑
m=1
[ ND,m∑
d=0
D2md
Pd0m(1 + θDd)∑ND,m
d=0 pd0m(1 + θDd)
1 −
Pd0m(1 + θDd)
ND,m∑
d=0
pd0m(1 + θDd)

− 2
∑
1≤d<d′≤ND
DmdDmd′
Pd0mpd′0m(1 + θDd)(1 + θDd′)[
ND,m∑
d=0
pd0m(1 + θDd)
]2 ]. (4.26)
Equations (4.24), (4.25) and (4.26) provide the framework to calculate the power for case-
control studies.
Remark 4.1. In Chapter 3 some substitutes to the formulas in Little et al. (2010) were
proposed in order to derive the algorithm for the cohort study. Similar substitutes can be
made in providing the formulas for the case-control study. The first required substitute is
similar to that explained in Remark 3.2. Actually, to calculate the power based on a normal-
sampling approach (i.e. assuming normal distribution for the score statistic under the null
and sampling from alternative) the following formula which is assumed to be approximately
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normally distributed is used for the score test under null
Z =
dl
dθ
|θ=0
/√
varθ[
dl
dθ
|θ=0]. (4.27)
So, the variance included is under the parameter which is of interest (θ). However, the same
explanation as that in Remark 3.2 proves that the formula should be as follows,
Z =
dl
dθ
|θ=0
/√
varθ=0[
dl
dθ
|θ=0]. (4.28)
I can propose a closed-form formula for the power of case-control studies by assuming
a normal distribution for the score statistic under alternative. In the next Chapter I prove
the fact that the score statistic is as good normally distributed under the alternative as it is
under the null. The closed-form formula is as follows. It is obtained from the same argument
as that for the cohort study. So, I skip the proof.
P = 1 − P(N(µθ, σ2θ) < Qα)
= 1 − P(N(0, 1) < σ0Z1−α − µθ
σθ
). (4.29)
where α is the level of the test and
µθ = Eθ[
dl
dθ
|θ=0] , σθ =
√
varθ[
dl
dθ
|θ=0]
are calculated from equations (4.19) and (4.20).
Remark 4.2. Notice that just like the formula for the power of the cohort study, the formula
given in Little et al. (2010) for the power of case-control study needs to be changed as it
doesn’t take into account difference between variances of the score statistic under null and
alternative. For more information see Remark 3.2. In Section 6.5, some simulated data has
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been used that shows this fact.
4.1.1 Formula for the sample size
To provide a formula for the sample size, we need to assume a single stratum in order to
be able to solve the problem for S . From equation (4.29) we can write
Z0 = (
σ0
σθ
)Z1−α − Z1−P (4.30)
where Z0 = µθσθ . Notice that here µθ = Eθ[
dl
dθ |θ=0] and σθ = varθ[ dldθ |θ=0] are calculated from
equations (4.21) and (4.22). One can also check that equation (4.21) can be simplified to
Eθ[
dl
dθ
|θ=0] = θ S KK + 1
ND∑
d=0
pd0D2d −
[
ND∑
d=0
pd0Dd
]2
ND∑
d=0
pd0(1 + θDd)
. (4.31)
Therefore, we can write
Z0 =
θSH1√
SH2
where H1 and H2 are defined appropriately by applying equations (4.22) and (4.31). Now
using a similar argument as that used in subsection 3.1.1, one can derive the following formula
for the required number of cases in a case-control study with significance level α and desired
power P
S =
{ ND∑
d=0
D2dpd0(1 − pd0) − 2
∑
1≤d<d′≤ND
DdDd′ pd0pd′0
Kθ2

ND∑
d=0
pd0D2d−
ND∑
d=0
pd0Dd
2
ND∑
d=0
pd0(1+θDd)

2
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+ND∑
d=0
D2d
Pd0(1+θDd)
ND∑
d=0
pd0(1+θDd)
1 − Pd0(1+θDd)ND∑
d=0
pd0(1+θDd)
 − 2 ∑1≤d<d′≤ND DdDd′ Pd0pd′0(1+θDd)(1+θDd′ )ND∑
d=0
pd0(1+θDd)
2
θ2

ND∑
d=0
pd0D2d−
ND∑
d=0
pd0Dd
2
ND∑
d=0
pd0(1+θDd)

2
}
× (σ0
σθ
Z1−α − Z1−P)2. (4.32)
Remark 4.3. Since the main reference uses a different closed-form formula, the formula pro-
vided for the sample size of case-control studies is different too. In Section 6.6 I use some
simulated data to compare the required sample size based on formulas given here and in the
main reference.
4.1.2 Sampling algorithm to calculate the power for the case-control study
Using the formula derived above for the score test statistic, we can implement the sam-
pling procedure to find the power for the case-control studies. The algorithm for this proce-
dure is as follows:
• Step 0. Fix the effect size to be detected (i.e. parameter θ) and number of controls
per case (K).
• Step 1. Fix number of years of follow-up.
• Step 2. Break down the dataset into M strata where each stratum is defined based on
a combination of age and sex. Then, break down each strata into ND cells defined by
dose categories.
• Step 3. Obtain required information from the dataset. This include:
1. S m: Number of cases in stratum m.
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2. Dmd: Average dose of individuals in category d of dose in stratum m.
3.
(
(Pd0m)
ND
d=0
)M
m=1
: Probability that a non-diseased individual in stratum m falls in
category d of dose. These parameters can be calculated by dividing the total
number of non-diseased individuals in dose category d in stratum m by the total
number of non-diseased individuals in the stratum. Notice that since cancer is
a rare disease, Pd0m is approximately equal to the proportion of category d in
stratum m.
• Step 4. Sampling procedure:
– Step 4-1. Fix an stratum m ∈ M:
∗ Step 4-1-1. Find one sample (nd0m)NDd=0 by drawing from a multinomial distri-
bution with KS m trials and probabilities Pd0m.
∗ Step 4-1-2. Find one sample (nd1m)NDd=0 by drawing from a multinomial distri-
bution with S m trials and probabilities
Pd1m =
Pd0m(1 + θDd)
ND∑
d=0
Pd0m(1 + θDd)
.
– Step 4-2. Repeat Step 4-1 for all m ∈ M in order to find a complete sample. Then
calculate the value of the score test statistic for this sample using equation (4.28).
– Step 4-3. Check whether the value from step 4-1 is greater than Z1−α (α being
the level of the test, usually α = .05). If so, mark this trial as a success.
• Step 5. Repeat Step 4, 100, 000 times. The power is then calculated from
power =
# o f success f ul trials
100, 000
where successful trial is defined in Step 4-3.
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• Step 6. Return to Step 1 and choose another number of years of follow up.
• Step 7. For a different effect size or/and different number of controls per case return
to Step 0 and change θ or/and K.
62
Chapter 5
Further discussions on the procedures
In this chapter, we present some discussions that provide a new approach or some substi-
tute for the methods discussed in the previous chapters. In particular, we prove the normality
of the score test statistic under both null and alternative for both cohort and case-control
studies. We also argue that the formula for the Monte-Carlo Error (MCE) given in Little
et al. (2010) needs to be modified. We propose some possible substitutes. We discuss three
possible approaches that can be used to calculate the power for the epidemiological stud-
ies. This includes normal-sampling, normal-normal and sampling-sampling approaches. It
should be pointed out that Little et al. (2010) uses a normal-sampling approach to calculate
power. We also argue that the procedure presented for the cohort study can be used in
studies the measure of association of which is SIR (standardized incidence ratio) or SMR
(standardized mortality rate).
5.1 Monte-Carlo Error
When using Monte-Carlo estimation to evaluate any quantity, one usually gets some
error. The reason is that the finite number of samples is drawn and based on this samples the
desired quantity is estimated. However, if one draws another set of samples and recalculates
the estimated quantity based on the new samples, a different result will come out. Although
in most cases this difference is slight, there is no guarantee to get the same results. For
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instance, in our context we draw 100, 000 samples from alternative. Based on these samples
we find an approximate distribution for the score statistic under the alternative. Now, if we
draw another 100, 000 samples we will get another distribution which is (probably slightly)
different from the first one. Therefore, the value that we obtain for power would be different.
This fact reflects the issue of Monte-Carlo Error (MCE).
The MCE index in simulated studies is very important and should be addressed. Based
on MCE one can justify the number of repetitions in the Monte-Carlo procedure. However,
as noted in Koehler et al. (2009), most studies that use the Monte-Carlo procedure don’t
report MCE and don’t justify their number of repetitions. It is reported in Koehler et al.
(2009) that out of 223 reviewed papers only 8 report MCE. my main reference (Little et al.
2010) reports the MCE using the formula 1√
N
where N is the number of repetitions in the
Monte-Carlo. Notice that there is no general formula for MCE and this index should be
proposed based on the quantity of interest and the Monte-Carlo procedure to estimate it.
Some formulas for MCE to be used in different contexts are proposed in Koehler et al. (2009).
Here, we justify the formula proposed in Little et al. (2010) for MCE and explain why it
needs adjustment. We propose other approaches to deal with MCE. As mentioned above, in
my context different sample sets provide different estimated distributions for the score statis-
tic under the alternative. Therefore, we need a measure to compare these two distributions.
One possible approach is to calculate the average value of the distributions and evaluate
the precision of the Monte-Carlo based on the precision of this average. In other words, we
report the standard deviation of the sample means as the MCE whereby a sample we mean
a full simulated data from Monte-Carlo. According to CLT, this is given by σS√
N
where σS
is the standard deviation of the normalized score test statistic under the alternative and N
is number of repetitions. It is assumed in Little et al. (2010) that σS = 1. In the sequel,
we explain why this seems to be improper. The problem arises from the fact that in the
aforementioned reference the variance included in the formula of normalized score statistic
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is the variance under alternative (See Remark 3.3 and Remark 4.1 ). Since we are applying
the Monte-Carlo procedure to draw from alternative, the variance of the normalized score
statistic under alternative turns out to be 1. Therefore, regardless of the effect size (θ) and
the year of follow-up we always get a fixed MCE which is 1√
N
. Unfortunately, the issue is
not this simple! As explained in Remark 3.3, in such a case one can not assume the score
statistic under the null to be standard normal. In other words, there is a trade-off between
‘permanent standard normal distribution under the null’ and ‘fixed MCE’. If we would like to
use the formula proposed in Little et al. (2010) for the normalized score statistic, then each
time, depending on the alternative parameter θ and the year of follow-up, we need to adjust
the variance of the score statistic under the null to obtain the correct quantile corresponding
to the test significance level (α). On the other hand, if we would like to always keep the
score statistic under the null standard normal, we need to use the variance under the null to
normalize the score statistic (as explained in Remark 3.3 and Remark 4.1). This face is not
taken into account in Little et al. (2010) and at the same time assumes a standard normal
distribution for the score statistic under the null (which is evident from Table 1 and Table
2 in the said reference) and a fixed MCE.
It seems that a permanent standard normal distribution under null is more useful in my
context as it relaxes the need to adjust the score statistic under the null for different values
of θ and different years of follow-up. However, in such a case we get σS = σθσ0 where σθ and
σ0 are the variance of the score statistic under the alternative and null, respectively. As a
result, the MCE with N repetition is given by.
MCE =
σθ/σ0√
N
. (5.1)
Notice that this value depends on the study design, θ and years of follow-up. Assume that
we fix θ. To deal with the problem of MCE, one possible solution is to pick one value of
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N such that MCE for all the years of follow-up is smaller than the desired value. Another
possible approach is to obtain a fixed MCE by not using a fixed number of repetitions for
different years of follow-up but determine the number of repetitions independently. Using
Equation 5.1, we can see that the formula for the number of repetitions for each year of
follow-up is
NY =
(σθ/σ0MCE
)2 + 1.
where [·] stands for the integer part. It is recommended in Little et al. (2010) that .0032 as
a low MCE. In such a case, for each year of follow-up, the required number of repetition is
NY =
(σθ/σ0
.0032
)2 + 1.
In Section 6.2, simulated data has been used to compare the number of iterations that are
required to attain MCE = .0032.
5.2 Asymptotic normality of the score test statistic under null and
alternative
The well-known theorem of Rao, as presented in the first chapter, states that the score
test statistic under null is asymptotically normal. This means that assuming a large sample
size if one draws samples from null and plug in the score test statistics (at the null value), he
or she will get an approximately normal distribution. However, when it comes to alternative,
the Rao’s theorem doesn’t explicitly say anything. For the procedures proposed in this study,
we can see that the corresponding score statistic formulas have a nice form that forces them
to be asymptotically normal under both null and alternative for both cohort and case-control
studies. We present the proof below.
The key tool in my approach is to rely on an indirect application of Rao’s theorem rather
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than using a direct application as presented in the following theorem.
Theorem 5.1. Let M be a multinomial distribution with l possible outcomes with probabilities
(p1, · · · , pk). Let Di for 1 ≤ i ≤ k be some real numbers with
0 < D1 < D2 < · · · < Dk.
Then
k∑
i=1
miDi has an asymptotic normal distribution where each mi is the binomial distribu-
tion derived from multinomial M for the i-th outcome.
Proof. We set up an artificial experiment as follows: Assume that we have n dose categories
with average dose Di in each category i for 1 ≤ i ≤ k. Also, assume that we have a population
which is distributed among the dose categories with proportions pi for 1 ≤ i ≤ k. Let’s here
denote the ERR parameter with β and assume a linear dose effect model, i.e.
Risk ratio for group i of dose = 1 + βDi.
Then, using equation (3.7), we see that for such an experiment the score test statistic (as-
suming that we are testing for β = 0) is given by
dL
dβ
|β=0 =
k∑
i=1
miDi − N
k∑
i=1
piDi.
According to the Rao’s theorem this should be asymptotically normally distributed. Consid-
ering the fact that N
k∑
i=1
piDi is a fixed term, we conclude that
k∑
i=1
miDi has asymptotic normal
distribution. This proves the claim. 
Notice the difference between a direct and an indirect application of the Rao’s theorem.
If we were to use the Rao’s theorem directly, then for example in (3.7), we had to always
restrict to the case where binomial variables come from a multinomial distribution with
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probabilities (Pi j) (i.e. θ = 0) while Theorem 5.1 removes this restriction. So, we can write
the following corollaries.
Corollary 5.1. The score test statistic for the cohort study is asymptotically normal under
both null and alternative.
Proof. The score test statistic for the cohort study is given by
dL
dθ
|θ=0 =
I∑
i=1
 Ki∑
j=1
mi jDi j − Mi
Ki∑
j=1
pi jDi j
 .
Under the null, for a fixed 1 ≤ i ≤ I, {mi j}Kij=1 are binomial variables that come from a
multinomial distribution with Mi trials and probabilities {pi j}Kij=1. Under the alternative they
are again binomial variables that come from a multinomial distribution with probabilities
pii j =
pi j(1 + θDi j)
Ki∑
j=1
pi j(1 + θDi j)
.
In any case according to Theorem 5.1, ∑Kij=1 mi jDi j is asymptotically normal. Since multino-
mial distributions for 1 ≤ i ≤ I are independent and sum of independent normal variables is
again normal, we conclude that the score statistic under the null and alternative is asymp-
totically normal. 
Corollary 5.2. The score test statistic for the case-control study is asymptotically normal
under both null and alternative.
Proof. The score test statistic for the case-control study is given by
dl
dθ
|θ =
M∑
m=1
− 1K + 1
ND,m∑
d=0
nd0mDmd +
K
K + 1
ND,m∑
d=0
nd1mDmd
 .
Under the null for a fixed 1 ≤ m ≤ M each (nd0m)ND,md=0 and (nd1m)ND,md=0 are both binomial variables
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coming from two independent multinomial distributions both with probabilities (pd0m)ND,md=0 and
each with KS m and S m trials respectively. Under the alternative (nd0m)ND,md=0 is as before while
(nd1m)
ND,m
d=0 comes from a multinomial distribution with S m trials and probabilities
pd0m(1 + θDd0m)
ND,m∑
d=0
pd0m(1 + θDd0m)
.
In any case, according to Theorem 5.1
ND,m∑
d=0
nd0mDmd and
ND,m∑
d=0
nd1mDmd are asymptotically nor-
mally distributed. Since these are independent for each m and the multinomial distributions
are independent for all 1 ≤ m ≤ M, we conclude that the score test statistic for the case-
control study should be asymptotically normally distributed. 
5.3 Different approaches to calculate the power
Using the results from the previous section we can see that assuming a normal distribution
for the score statistic under both null and alternative is reasonable in case the asymptotic
assumption is met. If not, we can make no assumption on the distribution of neither of
them. Therefore, we can propose the following three methods to calculate the power for
both cohort and case-control studies:
1. Normal-sampling: As explained in subsection 3.1.2 and subsection 4.1.2, Little et al.
(2010) uses this approach. It assumes a normal distribution for the score test under
null and takes samples from the alternative to calculate the power. We would like to
refer to this procedure as normal-sampling. This procedure relies on the Rao’s theorem
that states the normality of the score test under the null.
2. Normal-normal: As we proved in the previous section, in procedures for both cohort
and case-control studies the score statistic under the alternative is as good asymptot-
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ically normal as it is under the null. Therefore, if we believe that the score statistic
under the null meets the asymptotic assumption, then it is very likely to meet the as-
sumption under the alternative. This suggests that in such a case using a closed-form
formula for the power is reasonable. In Chapters 3 and 4 we corrected the closed-form
formulas for the power that were proposed in Little et al. (2010). Therefore, as long
as the sample size is large enough we can be sure that those formulas provide reliable
results. Here, we will refer to the closed-form formula method as the normal-normal
procedure.
3. Sampling-sampling: What if the sample size is small? In such a case chances are that
score test under none of null and alternative is normal. Then, we can first calculate
the distribution of the score test under the null using a sampling procedure too! The
algorithm for this procedure is explained below.
In Section 6.5, we use some simulated data and compare the results for the power of cohort
and case-control studies based on all the methods explained above.
5.3.1 The sampling-sampling algorithm to calculate the power
All steps in the sampling-sampling algorithm are similar to those in algorithms described
in Sections 3.1.2 and 4.1.2. However, we need to add two extra steps and adjust another
step as described below:
The cohort study. We need to add two extra steps between steps 3 and 4, in the algorithm
described in Section 3.1.2, to determine the distribution of score statistic under the null.
Let’s denote these steps by Step ⋆ and Step ⋆⋆. The algorithm for these steps is as follows:
• Step ⋆. Define a vector named NL which is initially empty.
– Step ⋆-1. Fix i ∈ I and draw a sample from a multinomial distribution with Mi
trials and J possible outcomes each with probability (pi j)Jj=1.
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– Step ⋆-2. Repeat Step ⋆-1 for all i ∈ I. Then using formula (3.15) calculate the
value of the test statistic for this sample.
– Step ⋆-3. Add the value calculated in Step ⋆-2 to vector NL.
• Step ⋆⋆. Repeat Step ⋆, 100, 000 times. The vector NL now has 100, 000 components.
Sort them increasingly. For a test with significance level α chose the ([(1−α)×100, 000]+
1)-th component of the sorted NL vector as the threshold and denote it by TS (here
[·] stands for the integer part).
We also need to change Step 4-3:
- Step 4.3. Check whether the value from Step 4-2 is greater than TS . If so, mark it as a
success.
The case-control study. Again, we need to add two extra steps between steps 3 and 4, in
the algorithm described in subsection 4.1.2. Let’s use the same notation as above to refer to
these extra steps: Step ⋆ and Step ⋆⋆.
• Step ⋆. Define a vector named NL which is initially empty.
– Step ⋆-1.
∗ Step ⋆-1-1. Find one sample (nd0m)NDd=0 by drawing from a multinomial distri-
bution with KS m trials and probabilities (pd0m)NDd=0.
∗ Step ⋆-1-2. Find one sample (nd1m)NDd=0 by drawing from a multinomial distri-
bution with S m trials and probabilities (pd0m)NDd=0.
– Step ⋆-2. Repeat Step ⋆-1 for all m ∈ M. Then using formula (4.24) calculate
the value of the test statistic for this sample.
– Step ⋆-3. Add the value calculated in Step ⋆-2 to vector NL.
• Step ⋆⋆. Repeat Step ⋆, 100, 000 times. The vector NL now has 100, 000 components.
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Sort them increasingly. For a test with significance level α chose the ([(1−α)×100, 000]+
1)-th component of the sorted NL vector as the threshold and denote it by TS .
Again we need to change Step 4-3:
- Step 4.3. Check whether the value from Step 4-2 is greater than TS . If so, mark it as a
success.
5.4 A Bayesian approach to specifying a distribution for the power
To calculate the power, one has to pick a value for the alternative which is possibly as
close to the true value as possible. One possible approach is to pick the value based on
the studies already carried out. Since different studies might suggest different values (see
Section 7.1), choosing a single parameter might be kind of subjective. The methods we have
been discussing so far (following Little et al. (2010)) require the specification of a single
estimation.
One possible approach to deal with this problem is to specify a range (rather than a
single value) for the parameter and then implement a Bayesian model. Notice that in such
a case we obtain a distribution for the power rather than a single estimation.
A method to find such a distribution is suggested in Lunn et al. (2012; Section 5.3):
Based on a literature review find a range for the parameter of interest. Assume a normal
distribution for the parameter and consider the given range as the 67% interval,i.e., mean ±1
standard deviation. Using this information, calculate the mean and the standard deviation.
A big advantage of this approach is the inclusion of a range of possible values for θ rather
than relying on a single value. Notice, however, that this approach still carries some sort
of subjectivity as one might argue why we can assume a normal distribution and why the
observed range is considered the 67% interval.
Remark 5.1. Some previous major studies suggest that ERR parameter falls somewhere
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between .28 and .97 (see Section 7.1). We use the method explained above to find a normal
distribution for the ERR parameter. The mean value of this interval is .625. Also, we can
find the standard deviation based on the method proposed above.
.625 + σ = .97 ⇒ σ = .345.
Therefore, we can assign the following distribution to the ERR parameter
θ ∼ Normal(.625, .3452).
Remark 5.2. (The issue of running time). An important advantage of the normal-normal
approach that we proposed to calculate the power is that it remarkably reduces the running
time of the Bayesian model. Notice that if we were to use a normal-sampling approach, then
for any of the θ sample points, we have to draw a sample of size says 100, 000 subsequently,
from the corresponding multinomial distribution! Using the normal-normal approach, all we
need is the initial sample for θ as the power is calculated based on a closed-form formula.
This issue will be addressed in Remark 6.1 too.
5.5 Studies whose measure of association is SIR or SMR
Standardized Mortality Ratio (SMR) and Standardized Incident Ratio (SIR) are com-
monly used to deal with the problem of confounding. In these methods, the dataset stratified
by the confounder and the results are modified by comparison against a standard population.
There are some studies of ionizing radiation-cancer based on NDR that use this measure of
association (see for example Ashmore et al. (1998)). However, it has been noted in Zielinski
et al. (2008) that for occupational studies, SMR and SIR might be affected by another
problem called the ‘healthy worker effect’. As a result, the mortality and incidence rate
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in the exposed group might seem to be lower. This might not reflect the truth. Therefore,
measures of association such as risk ratio (for cohort studies) and odds ratio (for case-control
studies) which use an internal non-exposed group seem to be more reliable.
Despite all the facts stated above, here we explain why the power procedure derived for
the cohort study works for the SMR and SIR studies too. The main reason is that the power
procedure for the cohort study already uses stratification. This helps in solving the equation
for the number of cases in each stratum for SMR/SIR studies. Recall that from Equation
3.3, we could simply solve for Mi j the number of cases in category i j of dose. Using these
values we found the probabilities of the multinomial distributions which provide the basic
information for the power procedure. Notice that although this formula was calculated for
the stratified dataset, one can simply check that when there are no strata the argument to
derive the formula still works. For the SMR procedure, the general formula (assuming no
initial strata) for the SMR (or SIR) corresponding to category j of the dose can be written
as
S MR j =
# observed cases
# expected cases
=
N1 j
L1 j
p1 +
N2 j
L2 j
p2 + · · · + Nk jLk j pK
# cases in the standard population
(5.2)
where Ni j is number of cases in stratum i of the dose category j, Li j is its population and pi is
population of stratum i in the standard population. To derive a power procedure, we need to
obtain multinomial probabilities. For this purpose, we should find a value of Ni j. However,
using a single equation such as 5.2 it’s impossible as we have several unknown parameters.
But we are already breaking down the dataset into age+sex strata. Therefore, at each
stratum we only have a single age+sex stratum. The formula for SMR at strata i for dose
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group j is then
S MRi j =
Ni j
Li j
pi
Ni
=
Ni j/Li j
Ni/pi
=
probability o f being a case in the dose category i j (Dose = Di j)
probability o f being a case in stratum i o f standard population
(5.3)
This formula is similar to that given in (3.1). The only difference is that probability o f being a case in the non−
exposed category (Dose = 0) is replaced by probability o f being a case in stratum i o f standard population.
This doesn’t affect the formula derived for the multinomial probabilities and the final pro-
cedure. So, we will get the same procedure as that for the cohort study.
5.6 Derivation of an interval estimation for ERR parameter
In this section, I prove a theorem that allows derivation of an interval estimation for the
Relative risk of a general disease from the relative risks of some sub-diseases. This result
enables us to give an interval estimation for the ERR parameter of the general cancer from
the given ERR parameters of various cancer types. I will employ this fact in the next chapter.
Theorem 5.2. Let RRi for 1 ≤ i ≤ n be the mortality relative risk of some disease i. Let RR
denote the relative risk to die from any of the given diseases. Then we have,
min{RRi, i = 1, · · · , n} ≤ RR ≤ max{RRi, i = 1, · · · , n}. (5.4)
Proof. Let S e and S u denote the population of exposed and non-exposed groups. Let Nei and
Nui denote number of deaths of disease i in the exposed and non-exposed groups respectively.
Similarly, assume that Ne and Nu represent the total number of deaths (of any kind) in those
75
groups. Then the relative risk for disease i is given by
RRi =
Nei /S
e
Nui /S u
=
S u
S e
· N
e
i
Nui
. (5.5)
On the other hand, we can write
RR =
Ne/S e
Nu/S u
=
S u
S e
· N
e
Nu
=
S u
S e
· N
e
1 + · · · + Nen
Nu1 + · · · + Nun
. (5.6)
But we have
min{N
e
i
Nui
, i = 1, · · · , n} ≤ N
e
1 + · · · + Nen
Nu1 + · · · + Nun
≤ max{N
e
i
Nui
, i = 1, · · · , n} (5.7)
Putting (5.5), (5.6) and (5.7) together, we derive (5.4). 
Corollary 5.3. Let θ denote the ERR parameter for general cancer and assume that θi for
1 ≤ i ≤ n denotes the ERR parameter for various cancer types. Then we have
min{θi, i = 1, · · · , n} ≤ θ ≤ max{θi, i = 1, · · · , n}.
Proof. We can use Theorem 5.2 to write
min{RRi, i = 1, · · · , n} ≤ RR ≤ max{RRi, i = 1, · · · , n}.
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This together with the linear-dose effect implies that for any arbitrary mean dose D we have
min{1 + θiD, i = 1, · · · , n} ≤ 1 + θD ≤ max{1 + θiD, i = 1, · · · , n}.
This is equivalent to
1 +min{θi, i = 1, · · · , n}D ≤ 1 + θD ≤ 1 +max{θi, i = 1, · · · , n}D.
which implies
min{θi, i = 1, · · · , n} ≤ θ ≤ max{θi, i = 1, · · · , n}.

Remark 5.3. The reason why Theorem 5.2 is stated only for mortality and not for incidence
is that for the latter we might be not able to write Ne = Ne1 + · · · + Nen (similarly for Nu).
The issue of multiple diseases (such as multiple cancers) can be well resolved for mortality
but not for incidence. Multiple incidence of cancers, for instance, occurs when an individual
suffers from multiple types of cancer during his/her life (either concurrently or not). When
counting cases for different types of cancers, one should count it both towards all the relevant
Nei ,s (or Nui ,s). Now the problem is whether this individual should be counted as one case of
general cancer or two when calculating Ne (or Nu).
When it comes to mortality, we don’t have to deal with this problem as death marks a
unique event! If an individual with multiple cancers dies, the death is linked to latter cancer.
Therefore, categories of death from different types of cancer remain fairly disjoint even in
the presence of multiple cancers. One very unlikely possibility is dying simultaneously of
several cancers. In such a case, it is more reasonable to define a new category for the cause of
death including those cancer types collectively. So, categories for the cause of death remain
disjoint.
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For incidence, the issue is not so clear and the problem of counting multiple incidences (at
least for the ionizing radiation studies) has not been referred to in the literature. Therefore,
I prefer to keep Theorem 5.2 only for mortality. However, depending on the method used
to count cases, it might work for incidence as well. Furthermore, if multiple diseases are
infrequent, the said theorem still works “approximately” for incidence.
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Chapter 6
Simulation studies
In this chapter, we use some simulated data to visually prove the claims made in the
previous chapters and also to compare the different methods proposed. These includes:
1. The issue of Monte-Carlo error presented in Section 5.1.
2. Normality of score test statistic under null and alternative for cohort and case-control
studies
3. The proper formula to be used for the normalized score test statistic under the null.
4. Comparison of the closed-form formulas (normal-normal) proposed in Little et al.
(2010) and the one proposed in Chapters 3 and 4. We also compare both of them
against two other methods: Normal-sampling and Sampling-sampling as proposed in
Chapter 5.
5. Comparison of sample sizes for both cohort and case-control studies based on the
formulas proposed in Little et al. (2010) and those proposed in Chapters 3 and 4.
6. A Bayesian approach to provide a distribution for the power as described in Section
5.4
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6.1 simulated datasets
We will use the following datasets in our simulation studies. Each dataset is presented
using four pieces of information. these includes:
1. Mi a vector the length of which equals to the number of age+sex strata in the dataset
and each component of which represents the number of cases in each strata.
2. A matrix Di the dimension of which is n×m where n is number of dose categories and
m is number of age+sex strata. (Di) jk is the average of the dose in the j-th category
of dose in stratum k. In each column they are arranged increasingly.
3. A matrix Pi with the same dimension as Di. (pi) jk is the proportion of the population
of dose category j that contributes to stratum k.
4. A number Ki which is the number of controls assigned to a case in the case-control
study.
We define 6 datasets as follows:
• Dataset 1. M1 = (2, 5, 3, 2), K1 = 4 and
D1 =

1 1 2 1.5
1.8 4.3 3 2
2.9 7 4.7 4
 , P1 =

.5 .6 .5 .4
.3 .3 .27 .3
.2 .1 .23 .3

• Dataset 2. M2 = (5, 7), K2 = 4 and
D2 =
 1 23 7
 , P2 =
 .6 .2.4 .8

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• Dataset 3. M3 = (17, 15), K3 = 4 and
D3 =
 1 23 7
 , P3 =
 .6 .2.4 .8

• Dataset 4. M4 = (4, 18, 3, 11), K4 = 4 and
D4 =

1 1 2 1.5
2.8 3.3 3 2
7.9 4 4.7 4
 , P4 =

.8 .7 .2 .8
.1 .2 .5 .1
.1 .1 .3 .1

• Dataset 5. M5 = (4, 18, 3, 11), K5 = 4 and
D5 =

1 1 2 1.5
2.8 3.3 3 2
7.9 4 4.7 4
 , P5 =

.9 .05 .9 .1
0 .9 .09 0
.1 .05 .01 .9

• Dataset 6. M6 = (12), K6 = 4 and
D6 =

1.375
2.775
4.650
 , P6 =

.2075
.2925
.5

6.2 Monte-Carlo Error
As explained in Section 5.1, reference (Little et al. 2010) reports a fixed number of
iterations to obtain a desired MCE regardless of study design, effect size (θ) and years of
follow-up. However, as shown there all this factors should be taken into account. Bellow,
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we use our simulated datasets to obtain the required number of iterations for MCE = .0032
and θ = 2. Notice that if we use the formula given in Little et al. (2010), then we require
100, 000 iterations for both study designs and all datasets.
Table 6.1: Number of iterations for MCE = .0032 and θ = 2
6.3 Asymptotic normality of the score test statistic under null and
alternative
We proved asymptotic normality of the score test under the null and alternative for both
cohort and case-control studies in Section 5.2. Here, we use datasets defined in Section 6.1 to
visually see this fact. It should be pointed out that datasets defined in the aforementioned
section have been defined in pair: We manipulate one dataset in some specific way to see the
impact of manipulation on the asymptotic normality of the score test statistic. We check
asymptotic normality using the p-value validity test of the hypothesis test. This test relies
on the fact that F(X) ∼ U where X is a random variable, F is its CDF and U is the uniform
distribution. Notice that the flatter the p-value histogram, the better normally distributed
the score test statistic. Below we evaluate each dataset by drawing four histograms: Score
test statistic for cohort and case-control study under both null and alternative. All the his-
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Figure 6.1: Histograms of asymptotic normality for Dataset 1
tograms are drawn based on a simulation of size 100, 000. We set α = .05 and θ = 2 (for
alternative).
1. Dataset 1: Histograms for this dataset are given in Figure 6.1.
2. Dataset 6: Dataset 6 is obtained from Dataset 1 by collapsing 4 strata into 1. The
result for cohort in 6.2 suggests that more strata can cause the score statistic to be
better normally distributed.
3. Dataset 2: Histograms for this dataset are given in Figure 6.3.
4. Dataset 3: Dataset 3 is similar to Dataset 2. The only difference is that we increase
the number of observations from 12 to 32 which results in flatter histograms (Figure
6.4).
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Figure 6.2: Histograms of asymptotic normality for Dataset 6
Figure 6.3: Histograms of asymptotic normality for Dataset 2
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Figure 6.4: Histograms of asymptotic normality for Dataset 3
5. Dataset 4: Histograms for this dataset are given in Figure 6.5.
6. Dataset 5: Dataset 5 is obtained from Dataset 4 by making the population distribution
among dose categories very heterogeneous. It seems to worsen the normality (Figure
6.6).
6.4 Formula for the score test statistic for the normal-sampling ap-
proach
As pointed out in Remark 3.3 and Remark 4.1, the formula proposed for the score
test statistic for the normal-sampling approach in Little et al. (2010) needs modification
as it includes the variance under alternative rather than the variance under null. Here, we
specifically use Dataset 3 and check the normality of the score test statistic for the cohort
study based on both approaches. As Figure 6.7 and Figure 6.8 depict, the one with null
variance is much flatter!
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Figure 6.5: Histograms of asymptotic normality for Dataset 4
Figure 6.6: Histograms of asymptotic normality for Dataset 5
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Figure 6.7: Histograms of the score test statistic with null variance (Dataset 3-cohort)
Figure 6.8: Histograms of the score test statistic with alternative variance (Dataset
3-cohort)
6.5 Different approaches to calculate the power
In Section 5.3 we proposed three different approaches to calculate the power for both
cohort and case-control studies. this includes Normal-Sampling (N-S), Normal-Normal (N-
N) and Sampling-Sampling (S-S). Also for the N-N approach, we explained in Remark 3.2
and Remark 4.2 that the formulas are given in Little et al. (2010) (here referred to as old
formula) should be revisited. We provided substitute formulas (here referred to as new
formula). In Table 6.2 below we use all these methods and apply them to Datasets 1 to 5
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defined in Section 6.1 to derive the power for both cohort and case-control studies. From
this table, it is clear that: 1. The values for N-N (new formula) are always fairly close to
both values from N-S and S-S method. 2. The value given by N-N (old formula) is not close
to those of N-S and S-S and in many cases completely irrelevant!
6.6 Sample size
As explained in Remark 3.4 and Remark 4.3 the formulas proposed in Little et al. (2010)
(here referred to as old formula) for the sample size needs to be changed for both cohort
and case-control studies. In Table 6.3 we use two datasets to compare the sample size for
powers .8 and .9 based on the formulas proposed in Little et al. (2010) and also based on
the formulas we obtained in Chapters 3 and 4 (referred to as new formula).
Recall that for the sample size the dataset shouldn’t be stratified. So we improvise two
datasets:
1. Dataset 6: 2 Dose categories with average group dose D=(1,2)and distribution of
population among the dose groups p=(.4,.6). Also, let α = .05 and θ = 2. For the case
control study, assume 5 controls per case.
2. Dataset 7: : 4 Dose categories with average group dose D=(.5,1.4,2.5,4) and distribu-
tion of population among the dose groups p=(.5,.3,.15,.05). Also, let α = .1 and θ = 1.
For the case control study, assume 4 controls per case.
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Table 6.2: Comparison of power for Datasets 1 to 5 using four methods
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Table 6.3: Comparison of sample size based on old and new formulas
6.7 A Bayesian approach to specifying a distribution for the power
In Section 5.4 we explained a Bayesian method to find the power to include a range of
possible values for the ERR parameter rather than relying upon a single value. We illustrate
the proposed approach by applying it to dataset 4 to derive a distribution for the power of
the cohort study. We assume that the 67% interval for θ is [1, 3].
Using Winbugs, we can see that a sample of size 5000 converges to the distribution specified
for θ which is Normal(2,1). The history plot shows that convergence is attained with 5000
samples (Figure 6.9).
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Figure 6.9: History plot for 5000 samples from θ
Figure 6.10 shows the density plot of the drawn sample.
Figure 6.10: density plot for 5000 samples from θ
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Figure 6.11: Distribution of Power for the cohort study, dataset 4
Now, for each sample point, we can apply one of the three methods explained in Section
5.3 to calculate the corresponding power. Finally, we can make inference based on the power
sample we have found. The power distribution of the cohort study for dataset 4 is shown in
Figure 6.11. Based on the drawn sample, we can also find that there is 77% chance for this
study to have a power of .8 or higher.
Remark 6.1. In Remark 5.2, we addressed the issue of running time. Notice that for the
example presented above, if we use the normal-sampling approach, then we need to sample
500, 000, 000 times while using the normal-normal approach all we need is the initial sample
for θ of size 5000. We found the above power distribution using both methods. The running
time is dramatically different. Using the normal-normal approach the running time is only
.9 seconds while using the normal-sampling approach it is 1929 seconds!
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Chapter 7
Conclusion
In this thesis we considered procedures developed in Little et al. (2010) to calculate the
power of studies related to low-level doses of ionizing radiation and cancer health outcomes.
We explained the procedures with mathematical and statistical details and proposed several
substitutes to methods proposed in the mentioned reference to improve its performance.
The improvement includes: Changing the formula for the score statistic for both cohort and
case-control studies, proposing a more effective closed-form formula for the power, changing
the formula for the sample size and redefining the formula for the Monte-Carlo Error. We
also present a third method to calculate the power which is a sampling-sampling approach.
We laid out the algorithm to implement all the methods. This could help researchers who
are interested in carrying out the same kind of study in the future. We also proposed a
Bayesian approach to find distribution for the power. We address the issue of running time
for the Bayesian model to explain why a closed-form formula for the power is indispensable.
Therefore, the closed-form formula we proposed before becomes more prominent.
We also dealt with some secondary issues including Calculation of an interval estimation for
the ERR parameter and studies with SMR/SIR as the measure of association.
The R codes to implement all such methods are presented in the appendix. We illustrated
our work using simulation which is presented in Chapter 6.
Future work. Notice that one goal of this research is to calculate the power of ionizing
radiation-cancer studies based on the National Dose Registry of Canada. Since at this point
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the data is not ready, this will be done in the future. However, the required information to
analyze the data are presented in the following section.
7.1 Future studies
In this section, we provide the information required to analyze the National Dose Registry
of Canada (and any similar data set). The information provided in this section together with
the procedures we discussed in the previous chapters can be used to obtain the power of
cohort and case-control studies for all the possible years of follow-up. Based on the analysis,
it will be possible to suggest the best study design for ionizing radiation-cancer studies.
One can also evaluate the power of the previous studies and suggest the minimum year of
follow-up to attain a satisfactory power (widely considered to be 0.8).
7.1.1 Dose categories
The first step in analyzing the data is to break down the dose variable into a few dose
categories. We will use the following dose categories which are widely used in the literature.
In particular, Beebe et al. (1998) which is a well-known study comprising data from nuclear
power workers from 15 countries uses these categories to evaluate the ERR parameter. Other
ionizing radiation studies such as CVD studies useless and more the same categories (see for
example Zielinski et al. (2009)). The categories are as follow:
0, 0− < 5, 5− < 10, 10− < 20, 20− < 50, 50− < 100, 100− < 150, 150− < 200, 200− < 300,
300− < 400, 400− < 500, > 500.
94
7.1.2 The ERR parameter
Beebe et al. (1998) is the most well-known study to evaluate The Excess Relative Risk
parameter for ionizing radiation-cancer. This study combines information on nuclear power
workers in 15 countries across the world. It includes information of over 600, 000 individuals.
The ERR parameter as reported by this study is .97 S v−1 for all cancers excluding leukemia
and 1.93 S v−1 for leukemia excluding chronic lymphocytic leukemia. Another study (Kres-
tinina et al. 2005) that follows the residence of a highly radiation-exposed area in Russia
reports the parameter for all cancers to be .92 S v−1. A smaller ERR parameter is proposed
in Muirhead et al. (2009): .28 S v−1 . Notice also that BEIR V (BEIR V 1990) provides the
parameter for all types of cancer independently. However, cancer as a whole has not been
referred to there. Table 7.1 summarizes the results of this study on the ERR parameter of
various cancers. The ERR parameter for most major cancers is around 1 S v−1. Using this
table and Corollary 5.3, we can see that the ERR parameter for general cancer should fall
between 0 S v−1 and 8.3 S v−1. Although this range is wide, it matches the estimations pro-
vided in Beebe et al. (1998) and Krestinina et al. (2005). Notice that we can argue to shrink
this range as most ERR parameters are near 1 S v−1 except those for leukemia, salivary, brain
and thyroid cancers. If we remove these four cancer types, we will find out that the ERR
parameter for all cancers except those four types falls between 0 S v−1 and 2.3 S v−1. This
result seems to provide a fairly narrow interval that encompasses the estimations given in
Beebe et al. (1998) and Krestinina et al. (2005). It should be pointed out that the propor-
tion of leukemia, salivary, brain and thyroid cancers in all types of cancer is 2.6%, .3% 1.7%
and 3.3%, respectively (7.9% altogether). Therefore, the ERR parameter for general cancer
should be closer to that of all the other cancer types than to the ERR parameter of the four
types mentioned.
Based on all the results provided above, we judge that θ = 1 S v−1 is a fair choice for the
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ERR parameter. Notice that in our study dose amounts are given in milli-Sievert. Therefore,
we will use θ = .001 mSv−1.In a Bayesian approach, as explained in Section 5.4, we assume a
normal distribution for the ERR parameter with [.28, .97] as the 67% interval (±1 standard
deviation).
Table 7.1: BEIR V results on ERR parameter (per Sv) for various cancer types
7.1.3 What is the practical implications of this power study?
Using this power study, after analyzing the data, I will be able to provide three important
pieces of information for the epidemiologists working on the NDR:
• I can determine which study design is more suitale for the ionizing radiatoin-cancer
study based on the NDR, the cohort or the case-control study?
• There are already several papers in the litterature based on the NDR that try to
detect an ionizing radiation-cancer relationship. Many of such studies fail to detect a
significant result. I will be able to answer whether the insignificant result is due to
low power or not? If I realize that the power of such studies has been low, then the
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non-significant result should not be interpreted as a true lack of association between
ionizing radiation and cancer.
• Finally, I can propose the minimum number of the years of follow-up to attain a
satisfactory power (say 80%) based on the NDR. Therefore, for future epidemiological
studies, this important factor will be taken into account.
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Appendix
In this chapter we present the R programming codes used to implement the power models
discussed throughout the thesis.
# CODES FOR THE PROJECT: STATISTICAL POWEROF EPIDEMIOLOGICAL STUDIES TO
# DETEDCT THE EFFECT OF IONIZING RADIATION ON THE MORTALITY
# RATE FROMCANCER BASED ON THE NATIONAL DOSE REGISTRY OF CANADA
#ALL THE CODES AREWRITTEN BASEDONAVECTORIZATION APPROACHAS FAR AS
#POSSIBLE. WE TRY TO AVOID WRITING LOOPS TO SPEED UP CODES
#WHICH IS NECCESSARY IN THIS STUDY CINSIDERING LARGEDIMENSIONSWEDEALWITH.
#------------------------------------------------------------------------------------------------------------------------------------------
# COHORT STUDY
#function in this part might possibly takes all or some of the following five
# parameters:
# 1. M: a FIXED vector containing the totall number of cases (deaths) at
# each stratum of dataset.
# 2. D: a FIXED matrix the ij-th entry of which shows the average dose of
# individuals at the j-th cell in the i-th strata of dataset.
# 3. p: a FIXED matrix the ij-th entry of which represents the proportion
# of cases in the j-th cell of the i-th stratum of dataset.
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# 4. v: a matrix of VARIABLES the ij-th entry of which represents observed
# number of cases (deaths) at the j-th cell in the i-th stratum.
# of dataset. The i-th column of v (related to the i-th stratum) forms
# a multinomial variable.
# 5.theta: The true ERR parameter.
#-----------------------------------------------------------------------------------
#Non-normalized score function for cohort
score_coh_nonnrm<-function(M,D,p,v){
score<-sum(colSums(v*D)-M*colSums(p*D))
score
}
#TEST score_coh_nonnrm
score_coh_nonnrm(M0,D0,p0,v0) #PASSED
#--------------------------------------------
#Expectation of the non-normalized score for cohort under parameter theta.
expectation_score_coh<-function(M,D,p,theta){
cols_pD<-colSums(p*D)
expectation<-theta*sum(M*(colSums(p*D**2)-cols_pD**2)/(1+theta*cols_pD))
expectation
}
#--------------------------------------------
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#Variance of the non-normalized score for cohort under parameter theta.
variance_score_coh<-function(M,D,p,theta){
cols_pD<-colSums(p*(1+theta*D))
#print(cols_pD)
part1<-colSums((D**2)*t((t(p*(1+theta*D))/cols_pD))*(1-t((t(p*(1+theta*D))
/cols_pD))))
n_col<-length(M)
n_row<-nrow(D)
part2<-NULL
for(i in 1:n_col){
new_ent<-0
for(j in 1:(n_row-1)){
for(k in (j+1):n_row){
new_ent<-new_ent+(D[j,i]*D[k,i]*p[j,i]*p[k,i]*(1+theta*D[j,i])
*(1+theta*D[k,i]))
}
}
part2<-c(part2,new_ent)
}
part2<-part2/cols_pD**2
#print(part2)
variance<-sum(M*(part1-2*part2))
variance
}
#---------------------------------------------
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# Number of cases to be observed in a cohort study to acheive a desired power:
# For future studies, this function gives the required number of cases to
# be observed in order to achieve a desired power.
# only a single strata is assumed (e.g. no age/sex stratum is considered.
# The cohort is treated a single study).
# We need some prior knowledge to calculate the sample size:
# 1. First fix the number of dose categories. D which is a vector that represents
# average population dose at each category must be known.
# 2. p, The proportion of the population of interest which falls in category j
# of dose should be provided.
# In addition, we need the following information:
# 3. Specify alpha, the size of the test and pow, the desired power.
# 4.Fix theta which is the smallest effect size we wish to detect at the given power.
Num_cases_coh<-function(D,p,theta,alpha,pow){
D_mat<-matrix(D,nrow=length(D))
p_mat<-matrix(p,nrow=length(p))
var_0<-variance_score_coh(c(1),D_mat,p_mat,0)
var_theta<-variance_score_coh(c(1),D_mat,p_mat,theta)
p1<-sum(D**2*p)+theta*sum(D**3*p)
p2<-1+theta*sum(p*D)
p3<-sum(D*p)+theta*sum(D**2*p)
p4<-sqrt(var_0/var_theta)
p5<-theta*(sum(p*D**2)-(sum(p*D))**2)
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#print(list(p1=p1,p2=p2,p3=p3,p5=p5))
size_new_formula<-ceiling((((p1*p2)-p3**2)*(p4*qnorm(1-alpha)-qnorm(1-pow))**2)
/p5**2)
size_old_formula<-ceiling((((p1*p2)-p3**2)*(qnorm(1-alpha)-qnorm(1-pow))**2)/p5**2)
list(size_new_formula=size_new_formula,size_old_formula=size_old_formula)
}
#----------------------------------------------
# The following function can be used for two different tasks. First, it can take the
# essential characteristic of the dataset including D,p, M and theta as explained in
# the beginning of this section. Also takes the following extra parameters:
# 1. alpha: Size of the test.
# 2. n: Number of simulations.
# Then returns the power.
# The function can also be used to calculate proportion of rejected samples under null
# if we change the variance of test
# statistic from var_0 to to var_theta (in such a case parameter test_var should be set
# to anything other than ”n”).
power_coh<-function(M,D,p,theta,alpha,n,test_var=”n”){
var_0<-variance_score_coh(M,D,p,0)
var_theta<-variance_score_coh(M,D,p,theta)
if(test_var!=”n”){score_var<-var_0}
else{score_var<-var_theta}
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exp_theta<-expectation_score_coh(M,D,p,theta)
SE_ratio<-sqrt(var_0/var_theta)
if(test_var!=”n”){sim_probs<-p}
else{sim_probs<-t(t((p*(1+theta*D)))/(colSums(p*(1+theta*D))))}
vector_rejected<-NULL
n_row<-nrow(D)
n_col<-ncol(D)
for(k in 1:n){
one_samp<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
one_samp[,i]<-rmultinom(1,M[i],sim_probs[,i])
}
normalized_score<-score_coh_nonnrm(M,D,p,one_samp)/sqrt(score_var)
vector_rejected<-c(vector_rejected,normalized_score>qnorm(1-alpha))
}
power_sim<-mean(vector_rejected)
if(test_var!=”n”){return(power_sim)}
power_formula_old<-(1-pnorm(qnorm(1-alpha)-exp_theta/sqrt(var_theta)))
power_formula_new<-(1-pnorm(SE_ratio*qnorm(1-alpha)-exp_theta/sqrt(var_theta)))
list(power_sim=power_sim,power_formula_old=power_formula_old,
power_formula_new=power_formula_new)
}
#-----------------------------------------------
# The function below calculates the power based on a naive approach. i.e., assumes no
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# theoretical distribution for the score test statiastic neither under null nor under
# alternative. The idea is to construct the distribution of score under null
# experimentally and then take samples from alternative and compare it against the
# experimental distribution under null.
# The parameters are as before. There are two new parameters though:
# 1. n1: Number of samples to be drawn from null in order to derive its experimental
# distribution.
# 2. n2: Number of samples to be drawn from alternative to calculate the power.
power_coh_naive<-function(M,D,p,theta,alpha,n1,n2){
score_null<-NULL
vector_rejected<-NULL
n_row<-nrow(D)
n_col<-ncol(D)
sim_probs_null<-p
sim_probs_alter<-t(t((p*(1+theta*D)))/(colSums(p*(1+theta*D))))
for(k in 1:n1){
one_samp<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
one_samp[,i]<-rmultinom(1,M[i],sim_probs_null[,i])
}
score_null<-c(score_null,score_coh_nonnrm(M,D,p,one_samp))
}
treshold<-sort(score_null)[floor((1-alpha)*n1)+1]
for(k in 1:n1){
one_samp<-matrix(rep(0,n_row*n_col),nrow=n_row)
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for(i in 1:n_col){
one_samp[,i]<-rmultinom(1,M[i],sim_probs_alter[,i])
}
vector_rejected<-c(vector_rejected,score_coh_nonnrm(M,D,p,one_samp)>treshold)
}
mean(vector_rejected)
}
#-----------------------------------------------
#TEST normality of null and alternative:
# According to Rao’s theorem the score statistic under null is assymptotically normal.
# However, In their model (sample size), they assume a normal distribution for the
# score test under alternative as well. There is no theoretical approach to prove
# this claim. However, we can test normality of score under null and alternative
# using Monte-Carlo simulation. See the function below.
test_norm_coh<-function(M,D,p,theta,n,test_var=”n”){
var<-variance_score_coh(M,D,p,theta)
if(test_var!=”n”){expect<-0}
else{expect<-expectation_score_coh(M,D,p,theta)}
if(test_var!=”n”){sim_probs<-p}
else{sim_probs<-t(t((p*(1+theta*D)))/(colSums(p*(1+theta*D))))}
p_values<-NULL
score_dist<-NULL
n_row<-nrow(D)
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n_col<-ncol(D)
for(k in 1:n){
one_samp<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
one_samp[,i]<-rmultinom(1,M[i],sim_probs[,i])
}
normalized_score<-(score_coh_nonnrm(M,D,p,one_samp)-expect)/sqrt(var)
score_dist<-c(score_dist,normalized_score)
p_values<-c(p_values,1-pnorm(normalized_score))
}
list(dist=score_dist,p_values=p_values)
}
#------------------------------------------------------------------------------------------------------------------------------------------
# CASE-CONTROL STUDY
#function in this part might possibly takes all or some of the following five
# parameters:
# 1. S: a FIXED vector containing the totall number of cases (deaths) at each
# stratum of dataset.
# 2. K: number of controls per case.
# 3. D: a FIXED matrix the ij-th entry of which shows the average dose of
# individuals at the j-th cell in the i-th strata of dataset.
# 4. p: a FIXED matrix the ij-th entry of which is given by:
# (non-diseased individuals in cell j of stratum i)
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# /(total number of non-diseased individuals in stratum i)
# 5. n_0: a matrix of VARIABLES the ij-th entry of which represents number of
# controls that fall in the j-th cell of the
# i-th stratum of dataset. The i-th column (related to the i-th stratum) forms
# a multinomial variable.
# 6. n_1: a matrix of VARIABLES the ij-th entry of which represents number of cases
# (deaths) that fall in the j-th cell of the
# i-th stratum of dataset. The i-th column (related to the i-th stratum) forms a
# multinomial variable.
# 7.theta: The true EOR parameter.
#-----------------------------------------------------------------------------------
#Non-normalized score function for case-control
score_cascnt_nonnrm<-function(D,K,n_0,n_1){
score<-sum((-1/(K+1))*colSums(n_0*D)+(K/(K+1))*colSums(n_1*D))
score
}
#-------------------------------------------------
#Expectation of the non-normalized score for case-control under parameter theta.
expectation_score_cascnt<-function(S,K,p,D,theta){
expectation<-(K/(K+1))*sum(S*colSums((t(t(p*(1+theta*D))
/colSums(p*(1+theta*D)))-p)*D))
expectation
}
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#-------------------------------------------------
#Variance of the non-normalized score for cohort under parameter theta.
variance_score_cascnt<-function(S,K,p,D,theta){
n_col<-length(S)
n_row<-nrow(D)
cols_pD<-colSums(p*(1+theta*D))
#cat(”cols_pD”,cols_pD,”\n”)
part0_1<-colSums((D**2)*p*(1-p))
#cat(”part0_1”,(D**2)*p*(1-p),”\n”)
part0_2<-NULL
for(i in 1:n_col){
new_ent<-0
for(j in 1:(n_row-1)){
for(k in (j+1):n_row){
new_ent<-new_ent+(D[j,i]*D[k,i]*p[j,i]*p[k,i])
}
}
part0_2<-c(part0_2,new_ent)
}
#cat(”part0_2”,part0_2,”\n”)
part1_1<-colSums((D**2)*t((t(p*(1+theta*D))/cols_pD))*(1-t((t(p*(1+theta*D))
/cols_pD))))
#cat(”part1_1”,part1_1,”\n”)
part1_2<-NULL
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for(i in 1:n_col){
new_ent<-0
for(j in 1:(n_row-1)){
for(k in (j+1):n_row){
new_ent<-new_ent+(D[j,i]*D[k,i]*p[j,i]*p[k,i]*(1+theta*D[j,i])*(1+theta*D[k,i]))
}
}
part1_2<-c(part1_2,new_ent)
}
part1_2<-part1_2/cols_pD**2
#cat(”part1_2”,part1_2,”\n”)
variance<-(K/(K+1)**2)*sum(S*(part0_1-2*part0_2))+(K/(K+1))
**2*sum(S*(part1_1-2*part1_2))
variance
}
#---------------------------------------------------
# Sample size for case-control studies with K control per case:
# This function gives number of cases to be included in a study with K control per
# case in order to acheive the desired power.
# Notice that unlike the cohort studies where the sample size couldn’t be directly
# calculated (rather, we only got number of
# cases to be observed as study goes on), for the case-control we can calculate the
# sample size. To determine the sample size (# of cases) for future studies assuming
# only a single strata (e.g. no age/sex stratum is considered.
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# The cohort is treated a single study). We need some prior knowledge to calculate
# the sample size:
# 1. First fix the number of dose categories. D which is a vector that represents
# average population dose at each category must be known.
# 2. p, The proportion of the non-diseased population of interest which falls in
# category j of dose should be provided.
# In addition, we need the following information:
# 3. Specify alpha, the size of the test and pow, the desired power.
# 4.Fix theta which is the smallest effect size we wish to detect at the given power.
Num_cases_cascnt<-function(K,p,D,theta,alpha,pow){
D_mat<-matrix(D,nrow=length(D))
p_mat<-matrix(p,nrow=length(p))
var_0<-variance_score_cascnt(c(1),K,p_mat,D_mat,0)
var_theta<-variance_score_cascnt(c(1),K,p_mat,D_mat,theta)
SE_ratio<-sqrt(var_0/var_theta)
#print(SE_ratio)
pD<-sum(p*(1+theta*D))
part0_1<-sum((D**2)*p*(1-p))
part0_2<-0
for(j in 1:(length(D)-1)){
for(k in (j+1):length(D)){
part0_2<-part0_2+(D[j]*D[k]*p[j]*p[k])
}
}
114
part1_1<-sum(((D**2)*(p*(1+theta*D))/(pD))*(1-(p*(1+theta*D))/(pD)))
sum((D**2)*p*(1-p))
part1_2<-0
for(j in 1:(length(D)-1)){
for(k in (j+1):length(D)){
part1_2<-part1_2+(D[j]*D[k]*p[j]*p[k]*(1+theta*D[j])*(1+theta*D[k]))
}
}
part1_2<-part1_2/pD**2
part2<-((sum(p*D**2)-(sum(p*D))**2)/(pD))**2
size_new_formula<-ceiling(((SE_ratio*qnorm(1-alpha)-qnorm(1-pow))
**2*((part0_1-2*part0_2)+K*(part1_1-2*part1_2)))/(K*theta**2*part2))
size_old_formula<-ceiling(((qnorm(1-alpha)-qnorm(1-pow))**2*((part0_1-2*part0_2)+
K*(part1_1-2*part1_2)))/(K*theta**2*part2))
list(size_new_formula=size_new_formula,size_old_formula=size_old_formula)
}
#---------------------------------------------------
# The following function takes the essential characteristic of the dataset including
# S,K,p,D and theta as explained in the beggining
# of this section. Also takes the following extrta parameters:
# 1. alpha: Size of the test.
# 2. n: Number of simulations.
# Then returns the power.
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power_cascnt<-function(S,K,p,D,theta,alpha,n){
var_0<-variance_score_cascnt(S,K,p,D,0)
var_theta<-variance_score_cascnt(S,K,p,D,theta)
exp_theta<-expectation_score_cascnt(S,K,p,D,theta)
SE_ratio<-sqrt(var_0/var_theta)
sim_probs_control<-p
sim_probs_case<-t(t((p*(1+theta*D)))/(colSums(p*(1+theta*D))))
vector_rejected<-NULL
n_row<-nrow(D)
n_col<-ncol(D)
for(k in 1:n){
one_samp_control<-matrix(rep(0,n_row*n_col),nrow=n_row)
one_samp_case<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
one_samp_control[,i]<-rmultinom(1,K*S[i],sim_probs_control[,i])
one_samp_case[,i]<-rmultinom(1,S[i],sim_probs_case[,i])
}
normalized_score<-score_cascnt_nonnrm(D,K,one_samp_control,one_samp_case)
/sqrt(var_0)
vector_rejected<-c(vector_rejected,normalized_score>qnorm(1-alpha))
}
power_sim<-mean(vector_rejected)
power_formula_new<-(1-pnorm(SE_ratio*qnorm(1-alpha)-exp_theta/sqrt(var_theta)))
power_formula_old<-(1-pnorm(qnorm(1-alpha)-exp_theta/sqrt(var_theta)))
list(power_sim=power_sim,power_formula_old=power_formula_old,
power_formula_new=power_formula_new)
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}#---------------------------------------------------
# The function below calculates the power based on a naive approach. i.e., assumes no
# theoretical distribution for the
# score test statiastic neither under null nor under alternative. The idea is to
# construct the distribution of score under null
# experimentally and then take samples from alternative and compare it against the
# experimental distribution under null.
# The parameters are as before. There are two new parameters though:
# 1. n1: Number of samples to be drawn from null in order to derive its
# experimental distribution.
# 2. n2: Number of samples to be drawn from alternative to calculate the power.
power_cascnt_naive<-function(S,K,p,D,theta,alpha,n1,n2){
score_null<-NULL
vector_rejected<-NULL
n_row<-nrow(D)
n_col<-ncol(D)
sim_probs_control<-p
sim_probs_case<-t(t((p*(1+theta*D)))/(colSums(p*(1+theta*D))))
for(k in 1:n1){
one_samp_control<-matrix(rep(0,n_row*n_col),nrow=n_row)
one_samp_case<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
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one_samp_control[,i]<-rmultinom(1,K*S[i],sim_probs_control[,i])
one_samp_case[,i]<-rmultinom(1,S[i],sim_probs_control[,i])
}
score_null<-c(score_null,score_cascnt_nonnrm(D,K,one_samp_control,one_samp_case))
}
treshold<-sort(score_null)[floor((1-alpha)*n1)+1]
for(k in 1:n2){
one_samp_control<-matrix(rep(0,n_row*n_col),nrow=n_row)
one_samp_case<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
one_samp_control[,i]<-rmultinom(1,K*S[i],sim_probs_control[,i])
one_samp_case[,i]<-rmultinom(1,S[i],sim_probs_case[,i])
}
vector_rejected<-c(vector_rejected,score_cascnt_nonnrm(D,K,one_samp_control,
one_samp_case)>treshold)
}
mean(vector_rejected)
}
#---------------------------------------------------
#TEST normality of null and alternative:
# According to Rao’s theorem the score statistic under null is assymptotically normal.
# However, In their model (sample size), they assume a normal distribution for the
# score test under alternative as well.
# There is no theoretical approach to prove this claim. However, we can test normality
# of score under null and alternative
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# using Monte-Carlo simulation. See the function below.
test_norm_cascnt<-function(S,K,p,D,theta,n){
var<-variance_score_cascnt(S,K,p,D,theta)
expect<-expectation_score_cascnt(S,K,p,D,theta)
sim_probs_control<-p
sim_probs_case<-t(t((p*(1+theta*D)))/(colSums(p*(1+theta*D))))
score_dist<-NULL
p_values<-NULL
n_row<-nrow(D)
n_col<-ncol(D)
for(k in 1:n){
one_samp_control<-matrix(rep(0,n_row*n_col),nrow=n_row)
one_samp_case<-matrix(rep(0,n_row*n_col),nrow=n_row)
for(i in 1:n_col){
one_samp_control[,i]<-rmultinom(1,K*S[i],sim_probs_control[,i])
one_samp_case[,i]<-rmultinom(1,S[i],sim_probs_case[,i])
}
normalized_score<-(score_cascnt_nonnrm(D,K,one_samp_control,one_samp_case
)-expect)/sqrt(var)
score_dist<-c(score_dist,normalized_score)
p_values<-c(p_values,1-pnorm(normalized_score))
}
list(dist=score_dist,p_values=p_values)
}
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#---------------------------------------------------
# The function below puts out the p-vlue plots for null and alternative for both
# cohort and case-control in a single image. The parameteers are as before.
# There are 3 extra parameters:
# 1. r: The dataset number to be printed on the plots and (if applicable)
# stored image.
# 2. sim: Number of simulations. Default is 10000.
# 3. save: to store or not the image. default is ”no”. Any other string value
# results in image to be stored in the directory.
plot_norm_altogether<-function(M,K,p,D,theta,r,sim=10000,save=”no”){
test_coh_null<-test_norm_coh(M,D,p,0,sim)
test_coh_alter<-test_norm_coh(M,D,p,theta,sim)
test_null_cascnt<-test_norm_cascnt(M,K,p,D,0,sim)
test_alter_cascnt<-test_norm_cascnt(M,K,p,D,theta,sim)
if(save!=”no”){
jpeg(paste(”dataset”,r,”.jpeg”))
}
par(mfrow=c(2,2))
hist(test_coh_null$p_values,main = paste(”dataset”,r,”-null (cohort study)”),
xlab = ”p-value”,xlim=c(0,1),breaks = seq(from=0, to=1, by=.1))
hist(test_coh_alter$p_values,main = paste(”dataset”,r,”-alternative (cohort study)”)
,xlab = ”p-value”,xlim=c(0,1),breaks = seq(from=0, to=1, by=.1))
hist(test_null_cascnt$p_values,main = paste(”dataset”,r,”-null (case-control study)”)
,xlab = ”p-value”,xlim=c(0,1),breaks = seq(from=0, to=1, by=.1))
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hist(test_alter_cascnt$p_values,main = paste(”dataset”,r,
”-alternative (case-control study)”),xlab = ”p-value”,xlim=c(0,1),
breaks = seq(from=0, to=1, by=.1))
if(save!=”no”){
dev.off()
}
}
#---------------------------------------------------
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